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The primary goal of this study was to characterize the role of GPR109A in the rostral ventrolateral
medulla (RVLM) in blood pressure (BP) regulation and to elucidate the mechanisms involved in
the hypertensive response elicited by central GPR109A activation. The central hypothesis of this
study was “central GPR109A activation causes neuronal oxidative stress and pressor response via
local glutamate/prostaglandins release”. The data provide the first evidence for GPR109A
expression in the RVLM, the major cardiovascular regulatory nucleus of the brainstem, and in
pheochromocytoma cell line (PC12 cells), used as surrogates of the RVLM neurons. GPR109A co-
localization was evident in tyrosine hydroxylase (TH)-expressing neurons and in PC12 cells. The
anti-hyperlipidemic drug, nicotinic acid (NA) a known GPR109A agonist that activate the receptor
and Ca2+-dependently release prostaglandins (PGs), was used in the study. Our findings
demonstrated that intra-RVLM activation of GPR109A receptors with NA produced a robust dose-
dependent glutamate-like elevation in sympathetic tone and BP in normotensive conscious male
Sprague Dawley (SD) rats. The pressor response was abolished by prior blockade of the NMDA
glutamate receptor (NMDAR) using 2-amino-5-phosphonopentanoic acid (AP5) or the prostanoid
EP3 receptor (EP3R) using N-[(5-Bromo-2-methoxyphenyl) sulfonyl]-3-[2-(2-
naphthalenylmethyl)phenyl]-2-propenamide (L-798106). Further, the NA pressor response was
exacerbated by a prior application of the glutamate uptake inhibitor, L-trans-Pyrrolidine-2,4-
dicarboxylic acid (PDC). Ex vivo studies revealed that intra-RVLM GPR109A activation (NA;
20μg) increased local prostaglandin E2 (PGE2) levels, enhanced RVLM ERK1/2 and nNOS
phosphorylation and increased c-Fos immunoreactivity. Further, NA induced oxidative stress in
the RVLM of NA-treated rats (increased ROS levels and NADPH oxidase activity and decreased
catalase activity). Prior EP3R blockade (L-798106) abrogated the biochemical and the pressor
response caused by intra-RVLM NA. NMDAR (AP5) or EP3R blockade similarly abolished NA-
mediated pressor response, indicating the involvement of both glutamate and PGE2 in this effect.
Selective inhibition of RVLM nNOS (Nω-propyl-L-arginine; NPLA) abolished the intra-RVLM
NA-evoked pressor response. Further, NPLA abrogated the GPR109A-mediated increases in
RVLM nNOS phosphorylation and c-Fos and ROS levels. Our in vitro (PC12) studies supported
and extended the in-vivo findings as NA increased Ca2+, PGE2, L-glutamate and NO levels as well
as ROS levels in cultured PC12 cells. The increase in L-glutamate level is likely mediated by
PGE2/EP3R because L-798106 attenuated NA or PGE2-evoked L-glutamate release. The above-
mentioned effects are mediated via GPR109A because the use of the inactive isomer, IsoNA failed
to produce any hemodynamic or biochemical changes. Further, NA failed to increase Ca2+ or L-
glutamate levels in PC12 cells following siRNA-evoked GPR109A knockdown. Collectively, these
studies provide insight into identifying the role of central GPR109A activation in cardiovascular
regulation in conscious animals and the potential mechanisms involved in this effect.
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CHAPTER ONE-GENERAL INTRODUCTION
1.1. G-Protein Coupled Receptor 109A
GPR109A (also known as hydroxy-carboxylic acid receptor 2 (HCA2), HM74a, or
NIACR1) is a G protein coupled receptor (GPCR) of the Gi subtype. The receptor is the
molecular target for nicotinic acid (NA). NA is taken as a dietary supplement (vitamin B3) or in
high doses as anti-hyperlipidemic drug for treating hyperlipidemia and associated cardiovascular
disorders (1975; Canner et al., 1986; Carlson, 2005).
1.1.1. Expression and Distribution of GPR109A
GPR109A is widely expressed in white and brown adipose tissue, keratinocytes and
various immune cells including monocytes, macrophages, neutrophils and dendritic cells
including Langerhans cells (Soga et al., 2003; Tunaru et al., 2003; Wise et al., 2003; Hanson et
al., 2010), and likely in microglia (Penberthy, 2009).
1.1.2. GPR109A Ligands
GPR109A can be activated by either endogenous or exogenous ligands. D-ß-
hydroxybutyrate (DHB) is the endogenous ligand of GPR109A. DHB reaches the µM-mM
concentration range needed to activate GPR109A only under starvation condition to initiate
survival homeostatic mechanisms that involves regulating its own production, preventing
ketoacidosis, and regulating fat utilization (Taggart et al., 2005).
An increasing number of exogenous ligands for GPR109A receptor are now known among
which NA, also known as niacin, is most clinically used. NA is prescribed as anti-hyperlipidemic
2medication or as a vitamin supplement. Similar to DHB, NA only activates the receptor, when
used in mega doses as anti-hyperlipidemic drug (Brown et al., 2001; Whitney et al., 2005).
Representative structures of different GPR109A ligands and their chemical classes are included
in Fig. 1.1.
3Figure 1. 1. GPR109A ligands
Representative exogenous GPR109A ligands and their chemical classes, modified from (Blad et
al., 2011).
4
51.1.3. Signaling Pathways Mediated Following GPR109A Activation
Activation of GPR109A by its agonist NA was reported to activate or inhibit versatile
signaling pathways including but not limited to the reduction in cAMP levels, ERK
phosphorylation, PLC/PKC activation and L-type Ca2+channel opening as discussed below.
1.1.3.1. Increase of Intracellular Ca2+
GPR109A receptor activation by its agonists was shown to increase the intracellular levels
of Ca2+ in a number of cell types, in particular macrophages and epidermal Langerhans cells
(Benyo et al., 2005; Benyo et al., 2006; Vanhorn et al., 2012; Gaidarov et al., 2013). This
increase is associated with the activation of  phospholipase A2 (PLA2) (Lin et al., 1992; Benyo
et al., 2006) and subsequent production of different prostaglandins (PGs) including prostaglandin
I2 (PGI2), prostaglandin E2 (PGE2), and prostaglandin D2 (PGD2) (Benyo et al., 2005).
1.1.3.2. Inhibition of Adenylyl Cyclase
GPR109A activation results in Gi/G0 protein-mediated inhibition of adenylyl cyclase,
leading to a decreased cAMP levels in a number of cell types (Soga et al., 2003; Tunaru et al.,
2003; Zhang et al., 2005). This effect is particularly important in adipocytes as it leads to a
reduced protein kinase A (PKA) activity and a decrease in hormone sensitive lipase activity
resulting in an inhibition of lipolysis and this is the base of the clinical application of its agonist,
NA, as anti-hyperlipidemic drug (Digby et al., 2009).
61.1.3.3. ERK1/2 Phosphorylation.
GPR109A activation by its agonists was reported to enhance ERK1/2 phosphorylation.
Niacin or acifran produced this effect in stably transfected CHO-K1 cells in a pertussis toxin-
sensitive way (Tunaru et al., 2003; Mahboubi et al., 2006; Tang et al., 2006). Further NA
stimulated Gβγ-dependent ERK1/2 phosphorylation in different cell lines (Walters et al., 2009;
Li et al., 2011).
1.1.4. NA Pharmacological Effects Mediated by GPR109A
Besides the anti-hyperlipidemic effect that is achieved with chronic NA therapy, a large
number of clinical and animal studies reported NA versatile lipid independent beneficial effects.
Interestingly, NA has an anti-inflammatory potential in a number of cells including adipocytes,
macrophages/monocytes and endothelial cells, most likely due its ability to reduce ROS
generation and pro-inflammatory cytokines expression in these preparations (Digby et al., 2009;
Ganji et al., 2009; Tavintharan et al., 2009; Digby et al., 2010). Additionally, NA (via
GPR109A) (Plaisance et al., 2009) can increase the levels of adiponectin, the cardiovascular
protective hormone (Pischon et al., 2004; Schulze et al., 2005). Further, NA was reported to
increase hemoxygenase-1 activity resulting in a vascular protective effect (Wu et al., 2012).
1.1.5. Flushing Reaction Associated with NA Therapy
As mentioned above GPR109A activation leads to higher intracellular Ca2+ levels that
results in the activation of PLA2 and subsequent production of different PGs. PGs through
activation of their own receptors, lead to the famous cutaneous flushing reaction associated with
7NA therapy (Andersson et al., 1977; Morrow et al., 1989). A number of interventions are
available to attenuate this flushing response either by inhibiting PGs synthesis with aspirin
(Eklund et al., 1979) or by blocking their receptors using the selective PGD2 antagonist,
laropiprant (Paolini et al., 2008).
1.2. Central Cardiovascular Regulation
The heart and blood vessels are subjects to both short and long-term central cardiovascular
regulations. The reflex evoked responses from arterial baroreceptors, chemoreceptor or
nociceptors contribute mainly to the short-term BP regulation, where’s long-term BP control is
mainly influenced by behavioral and disease state and usually involves hormonal imbalance, e.g
the renin angiotensin system (Dampney et al., 2002). A number of brain areas are involved in
central regulation of circulation and the maintenance of baseline arterial pressure. These areas
contribute unequally to their effects on the sympathetic outflow to the peripheral system. The
brainstem with its cardiovascular regulating nuclei is the principal regulatory site of central
sympathetic outflow, among which the rostral ventrolateral medulla (RVLM) is the key regulator
of basal BP activity.
1.3. Rostral Ventrolateral Medulla (RVLM) in Central Cardiovascular Regulation
The rostral ventrolateral medulla (RVLM) located in the ventral part of the brainstem,
lateral to the inferior olive, caudal to the facial nucleus, and ventral to the nucleus ambiguous
(Farlow et al., 1984; Dampney et al., 1987) is considered as the dominant source of excitatory
input to the arterial system. It receives inputs from peripheral arterial baroreceptors and
8peripheral chemoreceptors as well as from higher regions in the brain including periaqueductal
gray, the paraventricular nucleus (PVN) and the caudal ventrolateral medulla (Guyenet et al.,
1989; Kishi et al., 2001; Fisher and Paton, 2012). The RVLM contains both adrenergic and
noradrenergic neurons (Hokfelt T. et al., 1984). The most important of the RVLM neurons, is a
group of neurons called C1 neurons that synthesis adrenaline and release L-glutamate (DePuy et
al., 2013). Further, C1 neurons modulate the sympathetic activity by sending excitatory
discharges to the spinal cord and hence are involved in BP control (Dampney, 1994; Sved et al.,
2003; Guyenet, 2006b).
1.3.1. Different Players that Modulate BP Control in the RVLM
1.3.1.1. Role of Ca2+ and Excitatory Amino Acids
L-glutamate is the major neurotransmitter in the cardiovascular nuclei involved in the
neuronal control of the sympathetic drive and BP including the RVLM. In The CNS, higher
intracellular Ca2+ levels can induce different neurotransmitters release including L-glutamate
(Kish and Ueda, 1991; Berridge, 1998; Sudhof, 2004). L-glutamate activates fast-acting
ionotropic receptors, including NMDA and AMPA receptors whose activation leads to elevations
in intracellular Na+ and Ca2+ and increase nerve firing (Dingledine et al., 1999; Platt, 2007). The
increased Ca2+ level may lead to excitotoxicity and oxidative stress (Lipton and Rosenberg,
1994). In addition, L-glutamate can competitively inhibit the uptake of cysteine, the precursor of
glutathione (GSH), by inhibiting cystine/glutamate antiporter system leading to more oxidative
stress (Albrecht et al., 2010). Further, L-glutamate activates metabotropic receptors, which
trigger slower intracellular signaling pathways involving secondary messengers, protein kinases,
9and phosphatases (Gabor and Leenen, 2012). Activation of both receptor types by locally
injected L-glutamate or a glutamate analog leads to increased sympathetic nerve activity (SNA)
and a pressor response (Ito et al., 2003). However, in the RVLM, the NMDA receptor-mediated
fast and brief pressor response prevails (Kubo et al., 1993)
1.3.1.2. Impact of RVLM Oxidative Stress (Reactive Oxygen Species, ROS) on BP
A number of studies linked higher levels of ROS in the RVLM with hypertension
(Zimmerman et al., 2004; Kishi et al., 2008; Koga et al., 2008). There are many triggers that can
result in increased ROS levels including Ca2+ (Lipton and Rosenberg, 1994), angiotensin II
(Zimmerman et al., 2004), increased NADPH oxidase (NOX) activity (Griendling et al., 2000;
Bedard and Krause, 2007; Akki et al., 2009; Frey et al., 2009) and decreased activity or
expression of superoxide dismutase or catalase (ROS scavenging enzymes) (Dieterich et al.,
2000; Chan et al., 2006; Yoshitaka, 2008). The increase in ROS levels inhibits the activity of
voltage-gated potassium channels, thereby enhancing action potential propagation and increasing
neuronal activity and nerve firing leading to BP increase (Zimmerman et al., 2004; Zucker and
Gao, 2005).
1.3.1.3. Role of RVLM ERK1/2-nNOS Pathway in BP Regulation
ERK1/2 activation of nNOS-NO signaling in the RVLM reduces GABA release and elicits
sympathoexcitation (Chan et al., 2003; Martins-Pinge et al., 2007). There is also evidence that
NO is involved in L-glutamate-mediated neurotransmission in different brain areas (Southam et
al., 1991; Montague et al., 1994) including the RVLM (Martins-Pinge et al., 1999). Notably,
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higher NO levels can contribute to RVLM oxidative stress via its interaction with elevated
superoxide levels to produce peroxynitrite radical (Beckman et al., 1990), which causes dose-
dependent transient excitatory responses when injected into the RVLM (Zanzinger, 2002).
Conversely, others reported that intra-RVLM injection of NO precursor or donor decreases
sympathetic nerve activity and BP (Kagiyama et al., 1997). The mechanisms of these discordant
effects remain to be investigated.
1.3.1.4. Role of Prostaglandins
Higher levels of PGE2 in the CNS is shown to be sympathoexcitatory.
Intracerebroventricular (ICV) or local PGE2 injection in the hypothalamic paraventricular
nucleus is known to: (i) increase the sympathetic outflow/plasma catecholamines and BP in rats,
which is not observed with other PGs (Ando et al., 1995; Ariumi et al., 2002; Murakami et al.,
2002; Zhang et al., 2011); (ii) cause L-glutamate release in different CNS cell types (Bezzi et al.,
1998; Wang et al., 2015); and (iii) induce ROS generation via activating NADPH Oxidase
(NOX) activity (Wang et al., 2013a). Further, central (ICV) injection of PGE2 or misoprostol,
the prostaglandin EP receptor agonist, increases c-Fos, a marker of neuronal activity (Bullitt,
1990; Morgan and Curran, 1991), expression in different brain areas (Lacroix et al., 1996; Zhang
et al., 2011). Despite the critical involvement of the RVLM in central BP regulation, there are no
reports on the cardiovascular role of PGs in RVLM.
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1.4. Aims of Study
G protein-coupled receptor 109A (GPR109A) activation by its ligand nicotinic acid (NA)
in immune cells increases Ca2+ and PGs levels (Benyo et al., 2005). Ca2+ and high prostaglandin
E2 levels (PGE2) via EP3 receptor (EP3R) in the CNS induces L-glutamate release (Guemez-
Gamboa et al., 2011; Wang et al., 2013a), and oxidative stress (Lipton and Rosenberg, 1994;
Wang et al., 2013a) leading to sympathoexcitation and pressor response. Despite NA ability to
reach the brain in appreciable levels following its peripheral administration in the dose range that
is commonly prescribed for treating lipid disorders, the expression and function of its receptor
GPR109A in the RVLM remains unknown and the cardiovascular consequences of possible
central NA actions (via GPR109A activation) are not yet elucidated. Importantly, ROS
generation in cardiovascular/sympathetic activity regulating neuronal pool, such as the rostral
ventrolateral medulla (RVLM), increases sympathetic activity and BP. Therefore, the present
studies tested the central hypothesis that Ca2+-dependent L-glutamate release and oxidative
stress, triggered by NA activation of RVLM GPR109A, causes sympathoexcitation and a
pressor response. Additionally, the current study tested the corollary hypothesis that RVLM
PGE2 activation of EP3R plays a pivotal sympathoexcitatory role and serves intermediary
role in the GPR109A-mediated glutamate release and the subsequent biochemical events in
the RVLM that ultimately lead to the NA-evoked pressor response. To test our hypotheses
we followed a multi-level approach involving in vivo studies in conscious normotensive male
rats along with molecular studies conducted ex vivo, and in PC12 cells (exhibit neuronal
phenotype) (Okouchi et al., 2005) that were utilized as surrogates to RVLM neurons to perform
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experiments that were unachievable in vivo due to limited tissue amounts obtained from the
RVLM of treated and control rats.
Specific Aim 1: Experiments firstly examined the expression of GPR109A in the RVLM and in
PC12 cells and its spatial distribution in relation to tyrosine hydroxylase immunoreactive (TH-ir)
(pre-sympathetic) neurons. Second, the studies under this aim elucidated the cardiovascular
function of RVLM GPR109A by testing the hypothesis that the NA-evoked pressor response is
GPR109A-dependent.
Rationale: There are no reports on the expression of GPR109A protein in the brainstem
cardiovascular regulating nuclei including the RVLM. Therefore, the first objective of the studies
outlined under this aim was to determine whether GPR109A is expressed in the RVLM and in
PC12 cells , and its spatial distribution in the RVLM relative to different cell types, particularly
TH-ir neurons, which modulate the sympathetic activity and BP (Guyenet, 2006a; Kumagai et
al., 2012). The preliminary hemodynamic studies have shown that activation of RVLM
GPR109A leads to a pressor response associated with a decrease in the HR. Therefore, the
studies under this aim investigated the dose dependent effect of NA on different hemodynamic
and autonomic parameters that are involved in peripheral BP regulation by addressing the
following questions:
1- Is GPR109A expressed within the RVLM and in PC12 cells?
2- What is the spatial distribution in the RVLM relative to different cell types (neuronal and
glial cells), particularly TH-ir neurons?
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3- Does intra-RVLM administration of the GPR109A ligand, NA, produce dose-dependent
cardiovascular and autonomic effects that are GPR109A dependent?
Specific Aim 2: Studies under this aim tested the hypothesis that NA activation of RVLM
GPR109A increases intracellular Ca2+ levels that lead to L-glutamate (NMDAR)-dependent
oxidative stress and sympathoexcitation/pressor response.
Rationale: In the CNS, higher intracellular Ca2+ levels enhance neurotransmitters release, including
L-glutamate (Kish and Ueda, 1991; Berridge, 1998; Sudhof, 2004). Our preliminary BP findings
indicating a sharp L-glutamate-like increase in BP following intra-RVLM NA injection. Realizing
that NA activation increases intracellular Ca2+ in other cell types (Benyo et al., 2006), it is likely that
access of NA to central GPR109A might produce a similar effect and triggers L-glutamate release in
the RVLM, which is Ca2+-dependent (Tingley and Arneric, 1990). L-glutamate activation of fast-
acting ionotropic receptors, including NMDA and AMPA receptors increases intracellular Na+ and
Ca2+ as well as nerve firing (Dingledine et al., 1999). While the L-glutamate activation of the central
ionotropic or the metabotropic receptors (Gabor and Leenen, 2012) causes sympathoexcitation and a
pressor response (Ito et al., 2003), the NMDA receptor (NMDAR)-mediated fast and brief pressor
response prevails in the RVLM (Kubo et al., 1993). Further, elevations in Ca2+ (Lipton and
Rosenberg, 1994) and L-glutamate (Albrecht et al., 2010) levels lead to oxidative stress, and the
occurrence of the latter in the RVLM leads to sympathoexcitation and pressor response (Nishihara et
al., 2012). The studies under this aim are the first to elucidate the ability of NA to induce L-
glutamate release associated with oxidative stress and sympathoexcitation in the RVLM following
GPR109A activation by addressing the following questions:
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1. Does NA increase Ca2+ levels in neuronal preparations? And is this effect GPR109A
dependent?
2. Does NA induce L-glutamate release following GPR109A activation?
3. What is the effect of prior NMDA (AP5) and non NMDA L-glutamate receptors
blockade (CNQX) or L-glutamate uptake inhibition (PDC) on GPR109A (NA)-mediated
pressor response?
4. What is the role of ROS and NO in GPR109A (L-glutamate)-mediated pressor response?
Specific aim 3: The aim of these studies was to elucidate the role of PGs, in particular PGE2 via
EP3R activation, in the molecular mechanisms for the RVLM GPR109A (NA) mediated pressor
response in conscious rats, which focused on: NA-mediated increases in L-glutamate release,
RVLM neuronal/sympathetic activity (c-Fos expression, p-ERK1/2 and p-nNOS levels), and
oxidative stress (increased ROS levels, enhanced NOX activity and reduced catalase activity).
Rationale: The most common side effect of NA is the flushing reaction due to Ca2+-dependent
release of different PGs including prostaglandin I2 (PGI2), prostaglandin E2 (PGE2), and
prostaglandin D2 (PGD2) (Benyo et al., 2005). Centrally, ICV or local PGE2 injection in the
hypothalamic PVN increases the sympathetic outflow/plasma catecholamines and BP in rats,
which is not observed with other PGs (Ando et al., 1995; Ariumi et al., 2002; Murakami et al.,
2002; Zhang et al., 2011). PGE2 also causes L-glutamate release in different CNS cell types
(Bezzi et al., 1998; Wang et al., 2015), and induces ROS generation via activating NADPH
Oxidase (NOX) activity (Wang et al., 2013a). Further, central (ICV) injection of PGE2 or
misoprostol, the prostaglandin EP receptor agonist, increases c-Fos, a marker of neuronal
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activity, levels (Bullitt, 1990; Morgan and Curran, 1991) in different brain areas (Lacroix et al.,
1996; Zhang et al., 2011). Four subtypes of prostanoid receptors (EP1, EP2, EP3, and EP4) are
known to mediate the responses of PGE2 (Narumiya et al., 1999), among which EP3 receptor
(EP3R) mediates the central cardiovascular excitatory effects and renal sympathetic nerve
activity of PGE2 (Ariumi et al., 2002; Zhang et al., 2011).  Notably, the reported EP3R-
dependent activation of ERK1/2 (Chuang et al., 2006; Nicola et al., 2008) could be an important
mediator of sympathetic excitation because ERK1/2 activation of nNOS-NO signaling in the
RVLM reduces GABA release and elicits sympathoexcitation (Chan et al., 2003; Martins-Pinge
et al., 2007). Despite this knowledge, the role of EP3R in RVLM BP regulation has not been yet
investigated perhaps due lack of information on EP3R expression in the RVLM. Therefore,
experiments under this aim determined, for the first time, if EP3R is expressed in the RVLM, its
role in BP regulation and the possible intermediary role of released PGE2 and the activation of
RVLM EP3R in GPR109A (NA)-mediated sympathoexcitation and pressor response by
addressing the following questions:
1- Is EP3R expressed in the RVLM and in its surrogate cell line (PC12 cells)? Does intra-
RVLM GPR109A activation increase PGE2 levels in the RVLM and in PC12 cells?
2- Does intra-RVLM PGE2 increase BP via EP3R activation? Is this pathway implicated in
NA-mediated pressor response?
3- Does RVLM GPR109A activation lead to PGE2/EPR3R-dependent increase in L-
glutamate release, neuronal activity (c-Fos), oxidative stress (increased NOX activity and
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decreased catalase activity)? Are these biochemical effects dependent on ERK1/2/nNOS
phosphorylation?
4- Does nNOS inhibition using the selective nNOS inhibitor, Nω-Propyl-L-arginine
hydrochloride (NPLA) protect against NA-mediated adverse biochemical changes in the
RVLM and the subsequent pressor response?
Collectively, the findings of the present study provide the first comprehensive in vivo and
ex vivo evidence for the role of central GPR109A in central regulation of BP in conscious
normotensive rats, elucidating the different molecular mechanisms implicated in this effect, and
the clinical relevance of the findings. The latter is supported by identifying pharmacological
interventions for mitigating the NA-evoked pressor response.
CHAPTER TWO-MATERIALS AND METHODS
2.1. Preparation of the Rats
Male Sprague Dawley (SD) rats (320–370 g; Charles River Laboratories, Raleigh, NC)
were used in this study. Five days before the experiment, the animals were anesthetized using
ketamine (9mg/100 g) and xylazine (1mg/100 g) mixture i.p. followed by femoral artery
catheterization using a 5-cm PE-10 tube connected to PE-50 tubing filled with heparinized saline
(heparin 200 units/ml) for measurement of blood pressure (BP) and heart rate (HR) as in our
previous studies (Zhang and Abdel-Rahman, 2002b). Next unilateral stereotaxic insertion of a
23-guage stainless steel guide cannula (Small Parts, Miami, FL, USA) was performed to permit
microinjection into the RVLM (posterior -2.8 mm, lateral + 2.0 mm, dorsoventral -0.5 mm)
(Paxinos and Watson, 2005). The cannula was secured to the skull with dental cement (Durelon;
Thompson Dental Supply, Raleigh, NC, USA); pre- and post-operative buprenorphine (0.03
mg/kg) was used. At the end of the experiment, the position of the cannula was confirmed
histologically following intra-RVLM injection of fast green dye (EM Sciences, Cherry Hill, NJ).
These procedures are detailed in our recent study (Penumarti and Abdel-Rahman, 2014).
2.2. Blood pressure (BP) and heart rate (HR) measurements.
Blood pressure (BP) and heart rate (HR) measurements in conscious unrestrained rats were
conducted using ML870 (PowerLab 8/30) system and displayed and analyzed by LabChart (v. 7)
pro software (AD Instruments, Colorado Spring, CO) as in our reported studies (Ibrahim and
Abdel-Rahman, 2011; Nassar et al., 2011; Penumarti and Abdel-Rahman, 2014).  BP and HR
were allowed to stabilize in the conscious unrestrained rats at baseline, for at least 30 min,
followed by intra-RVLM microinjections of a constant volume (80nl) of different treatments
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through a 30-guage stainless steel injector.  At the end of BP recording period, animals were
euthanized with a lethal dose of pentobarbital sodium (>100 mg/kg). For DHE ROS and
immunofluorescence measurements, serial frozen brainstem sections (20 μm) containing the
RVLM rostrally from -12.8 to -11.8 mm relative to bregma (Paxinos et al., 1980) were cut at
−24°C with a microtome cryostat (HM 505 E; Microtome International GmbH, Walldorf,
Germany). For other different biochemical measurements, a 0.75 micropunch instrument was
used to collect micropunches (Stoelting Co., Wood Dale, IL) from the injected RVLM site (n =
4–5 each).
2.3. Cell Culture
Rat neuronal pheochromocytoma cell line (PC12 cells) was purchased from ATCC
(Rockville, MD). Cells were grown in F12k medium supplemented with horse serum (15%),
fetal bovine serum (2.5%), penicillin (100U/ml), and streptomycin (100U/ml) at 37°C in a
humidified incubator with 95% air and 5% CO2. The cells were cultured on corning cell bind
flasks for proper adherence followed by treatment with nerve growth factor (50ng/ml) until
completely differentiated to the neuronal phenotype according to the protocol of the supplier.
Passage was done every 3-5 days when cells reach confluence as in our previous studies (Zhang
et al., 2001).
2.4. Immunofluorescence
Colocalization studies in the RVLM were conducted according to the protocol used in our
previous reports (Wang and Abdel-Rahman, 2005; Ibrahim and Abdel-Rahman, 2012). Coronal
19
brainstem sections (20 μm) containing the RVLM from frozen brains of naïve untreated rats (n =
6) (rostrally from −12.8 to −11.8 mm relative to bregma) (Paxinos et al., 1980) were cut
followed by fixation in 4% paraformaldehyde in PBS for 20 min. The sections were then washed
with Tris-buffered saline (TBS) and incubated with blocking buffer (TBS buffer containing 0.2%
Tween 20 and 0.2% triton-X (TBST) and 10% normal donkey serum) at 4 °C for 2 hrs then with
mixtures of rabbit anti-GPR109A (1:200; Santa Cruz Biotechnology, CA, sc-134583) and one of
the following antibodies: mouse anti-tyrosine hydroxylase (MAB318), mouse anti-GFAP
(MAB360), mouse anti-NeuN (MAB377) (1:200; EMD Milipore, Temecula, CA) or mouse anti-
CD11b/c (1:200; Abcam, Cambridge, MA, ab1211) for 48 hrs at 4°C. Dual-labeling
immunofluorescence was revealed by incubation for 2 h in a mixture of fluorescein
isothiocyanate-conjugated donkey anti-rabbit and Cy5-conjugated donkey anti-mouse (1:200;
Jackson Immunoresearch Laboratories Inc., West Grove, PA). For TH-ir and c-Fos-ir neurons
colocalization studies, sections from frozen brains of rats received different treatment (n = 5-7)
were incubated for 48 h hrs at 4°C in a mixture of mouse anti-TH (1:200; EMD Milipore,
Temecula, CA) and rabbit polyclonal anti-c-Fos antibody (1:200; Santa Cruz Biotechnology,
CA). Dual-labeling immunofluorescence was revealed by incubating the sections for 2 h in a
mixture of Cy3-conjugated donkey anti-mouse and fluorescein isothiocyanate-conjugated
donkey anti-rabbit (1:200; Jackson Immunoresearch Laboratories Inc., West Grove, PA).
Negative controls (leaving out the primary or secondary antibody) as well as single labeled
controls were used to confirm the lack of nonspecific staining. Four to six sections per animal at
the level of RVLM were examined.
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PC12 cells were cultured on coverslips, washed with cold PBS and fixed with 4%
paraformaldehyde for 30 min, incubated with permeabilization buffer (0.1% Triton X-100 in
1xPBS) for 10 min, and then blocked with blocking buffer (1X TBS + 1% Bovine serum
albumin + 5% normal donkey serum+ 0.2% Tween20) for 2 hrs. The blocked cells were then
incubated with a mixture of rabbit anti-GPR109A (1:200; Santa Cruz Biotechnology, CA) and
mouse anti-tyrosine hydroxylase (1:200; EMD Milipore, Temecula, CA) for 24 hrs at 4°C.
Immunofluorescence was revealed by incubation for 2 hrs in a mixture of fluorescein
isothiocyanate-conjugated donkey anti-mouse and Cy3-conjugated donkey anti-rabbit (1:200;
Jackson Immunoresearch Laboratories Inc., West Grove, PA). A Zeiss LSM 510 confocal
microscope (Carl Zeiss Inc., Thornwood, New York) was used for the visualization, and
acquisition of the images at the same brightness and contrast settings.  Zen Lite 2011 software
was used for quantification of protein co-localization as in our previous studies (Ibrahim and
Abdel-Rahman, 2011).
2.5. Western Blot Analysis
Animals received a lethal dose of ketamine-xylazine mixture (i.p.), brains were removed,
flash frozen in 2-methylbutane on dry ice, and stored at -80°C until use. Brains were equilibrated
to -20°C and coronal sections containing the RVLM were obtained with a cryostat (HM 505E;
Microm International GmbH, Waldorf, Germany) according to atlas coordinates (Paxinos and
Watson, 2005). Tissues from the RVLM were collected bilaterally using a 0.75 mm punch
instrument as described in other studies (Ibrahim and Abdel-Rahman, 2011; Penumarti and
Abdel-Rahman, 2014) from approximately -12.8 to -11.8 mm relative to bregma (Paxinos and
21
Watson, 2005). Tissues were homogenized on ice by sonication in cell lysis buffer (20 mM Tris
pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium
pyrophosphate, 1 mM β-glycerolphosphate, 1 mM activated sodium orthovanadate) containing a
protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN). PC12 cells freshly subcultured
in 6-well plates were lysed using the same cell lysis buffer used for brain tissues and the total cell
lysates were used for the assay. Protein concentration in samples was quantified using a standard
Bio-Rad protein assay system (Bio-Rad Laboratories, Hercules, CA). Protein extracts (20 μg per
lane) were denatured at 97°C for 5 minutes, separated on NuPAGE Novex Bis-Tris 4 to 12%
SDS-PAGE gels (Invitrogen, Carlsbad, CA) using MOPS NuPAGE running buffer, and
electroblotted to nitrocellulose membranes using standard procedures. Nonspecific binding sites
on the membranes were blocked at room temperature in Odyssey blocking buffer (Li-Cor,
Lincoln, NE). For GPR109A receptor expression, membranes containing proteins from RVLM,
PC12 cells, liver (negative control) and spleen (positive control) were incubated overnight with
rabbit anti-GPR109A (1:500; Santa Cruz Biotechnology, CA) and mouse anti-GAPDH (1:
10,000; Abcam, Inc., MA) at 4°C. For EP3R expression, membranes containing proteins from
RVLM, PC12 cells and kidney (positive control) were incubated with anti EP3R polyclonal
antibody (1:500; Cayman, Ann Arbor, MI) and mouse anti-βactin (1:500; Abcam, Inc., MA) at
4°C overnight. The band was verified using EP3R antibody blocking peptide (1:500; Cayman,
Ann Arbor, MI). For ERK1/2 and nNOS measurements, membranes containing equal amounts of
RVLM protein from rats received different treatments were incubated overnight at 4°C with a
mixture of rabbit anti-phospho-nNOS (Ser1417) antibody (1:500; Thermo Fisher Scientific,
Waltham, MA) or rabbit anti-ERK1/2 (1:500; Cell Signaling, Danvers, MA) and mouse
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polyclonal anti-nNOS antibody (1:500; BD Biosciences, San Jose, CA) or mouse anti-p-ERK1/2
(1:500; Cell Signaling, Danvers, MA). Membranes were washed four times with phosphate-
buffered saline (PBS) containing 0.1% Tween 20 then incubated for 60 min with mixture
containing IRDye680-conjugated goat anti-mouse and IRDye800-conjugated goat anti-rabbit
(1:10000; LI-COR Biosciences). Bands representing phosphorylated and total protein were
detected simultaneously by using Odyssey Infrared Imager and analyzed with Odyssey
application software version (LI-COR Biosciences). Data represent mean values of integrated
density of different bands normalized to GAPDH or β-actin. For ERK1/2 and nNOS
phosphorylation, the ratio of p-nNOS or p-ERK1/2 were normalized to the corresponding total
nNOS (t-nNOS) or total ERK1/2 (t-ERK1/2), respectively.
2.6. (Ca2+)i Measurements
PC12 cells (150,000/ml) were cultured in 96 wells plate for 48 h, loaded for 30 min in the
dark at room temperature with cell permeant fura-2 AM (1 μM ; Molecular Probes, Invitrogen)
in HEPES-buffered saline solution (HBSS) (110 mM NaCl, 2.6 mM KCl, 1 mM MgSO4, 1 mM
CaCl2, 25 mM HEPES, 11 mM glucose, pH 7.4), after that the cells were washed, and incubated
for additional 30 min in HBSS alone. Fluorescence measurement (Ex λ: 340, 380 nm, Em λ: 510
nm) was done at 30 seconds, 2 and 4 min following different treatments. (Ca2+)i was determined
following the ratio method described by Grynkiewicz et al. (Grynkiewicz et al., 1985) and using
the equation, (Ca2+)i=Kd[(R-Rmin)/(Rmax-R)]×(Sf2/Sb2); where Rmax is the 340/380 nm ratio during
Ca2+ saturation condition obtained by using Titon-X 100 (0.1%) in regular HBSS, and Rmin is the
340/380 nm ratio during Ca2+-free conditions obtained by using EGTA (4 mM) in Ca2+ free
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HBSS buffer. Sf2 and Sb2 are the emission intensities at 380 nm excitation during Ca2+-free and
Ca2+-saturating conditions, respectively. Fura-2 Kd was set at 224 nM. Results are reported as
mean (Ca2+)i μM ± standard error of the mean (S.E.M).
2.7. L-glutamate Measurement
PC12 cells (150,000 cells/ml) were seeded in 12 wells plates with phenol red free F12k
media with serum for 48 hrs. On the day of experiment, the media was replaced with HBSS.
Different interventions were applied and the release of L-glutamate from PC12 cells in the buffer
was measured using Amplex Red kit (Molecular Probes, Invitrogen) following the manufacturer
instructions and reported studies (Drake et al., 2005; Medina-Ceja et al., 2015).
2.8. PGE2 Measurement
PGE2 level in RVLM homogenates (10 µg protein/sample) or the culture media of PC12
cells was measured using rat ELISA kits (Cayman, Ann Arbor, MI) according to the
manufacturer’s instructions. The absorbance was detected at 420 nm. A standard curve was
established using serial dilutions of PGE2 standard. PGE2 level in different samples was
calculated from the standard curve equation.
2.9. Quantification of Reactive Oxygen and Nitrogen Species
2.9.1. Dihydroethidium (DHE) Staining for ROS Detection.
Fresh unfixed brain sections with the RVLM (rostrally from -12.8 to -11.8 mm relative to
bregma) (Paxinos et al., 1980) were cut followed by incubation with 10 µM dihydroethidium
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(DHE) (Molecular Probes, Grand Island, NY) at 37°C in the presence of 5% CO2 in a moist
chamber for 30 min. Images were visualized with a Zeiss LSM 510 microscope. Three to five
images were acquired from four brainstem sections for each experimental condition.
Fluorescence intensity was quantified using Zen Lite 2011 software (Penumarti and Abdel-
Rahman, 2014).
2.9.2. Measurement of Reactive Oxygen Species by DCFH-DA.
PC12 cells (150,000/ml) were cultured in 96 wells plate for 48 hrs. 2′,7′-
Dichlorofluorescein diacetate (DCFH-DA) (Molecular Probes, Grand Island, NY) was dissolved
in methanol (20 mM) and kept at −20°C in the dark. Shortly before the experiment, it was freshly
diluted (1mM) with serum free cell culture media and incubated with the cells in the dark at
37°C for 30 min. The solution was discarded and the cells were washed twice with HBSS. The
treatments were then performed in serum free media. RVLM specimen from treated or control
rats were homogenized in phosphate-buffered saline (50 mM, pH 7.4) followed by centrifugation
(14,000 rpm, 20 min) and protein quantification of the supernatant using a Bio-Rad protein assay
system. Next, 150 µM freshly diluted DCFH-DA with phosphate buffer working solution was
added to RVLM homogenate supernatant (10 µl) in a 96-well plate for a final concentration of
25 µM DCFH-DA. 2′,7′-Dichlorofluorescein (DCF) was used to generate the standard curve.
Quantification was conducted by measuring fluorescence intensity using a microplate
fluorescence reader at excitation 485 nm/emission 530 nm. Kinetic readings were recorded for
60 min at 37°C. Reactive oxygen species (ROS) level was calculated as fold increase of DCF
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fluorescence of control as in our reported studies (McGee and Abdel-Rahman, 2012; Penumarti
and Abdel-Rahman, 2014).
2.9.3. Measurement of Nitric Oxide Level
PC12 cells (150,000/ml) were cultured in black 96 wells plates for 48 hrs. Cells were
incubated with 2 μM 2′,7′-Dichlorofluorescein diacetate (DAF-FM) in serum free medium for 30
min at 37°C in the dark. The cells were washed with HBSS to remove excess probe and then
incubated for an additional 15–30 min with HBSS to allow complete de-esterification of the
intracellular diacetate followed by the addition of different treatments. The fluorescence intensity
was quantified immediately using a microplate fluorescence reader with excitation wavelength at
495 nm and emission wavelength at 512 nm. NO levels are expressed as mean DAF-FM
fluorescence as in reported studies (Cortese-Krott et al., 2012).
2.10. Quantification of Catalase Activity
RVLM punches from injected sites were homogenized in 35 μl lysis buffer (20 mM Tris,
pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium
pyrophosphate, 1 mM β-glycerol-phosphate, 1 mM activated sodium orthovanadate, and 1 ug/ml
leupeptin) with protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN) followed by
centrifugation at 2,700 g for 4 min at 4°C. The supernatant was separated and assayed for protein
content (Bradford assay, Bio-Rad). Catalase activity was determined colorimetrically in 10 μg
protein using the Catalase Assay Kit (catalog no. CAT-100, Sigma-Aldrich, St. Louis, MO)
according to the manufacturer's instructions.
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2.11. Quantification of NADPH Oxidase Activity
NADPH oxidase (NOX) Activity was measured according to (La Favor et al., 2013) with
modification. For this assay, 30 μl of homogenate was added to 180 μl of a cocktail containing
10 μM Amplex Red (Molecular Probes, OR), 2.0 U/ml horseradish peroxidase, 30 U/ml
superoxide dismutase, and 100 μM NADPH (Sigma Aldrich, St. Louis, MO) in PBS.
Fluorescence intensity (530 nM ex/590 nM em) was measured continuously with a microplate
fluorescence reader at 37°C at 5 min intervals for 30 min, total NADPH-dependent H2O2
generated in the sample was used as an index of NOX activity. Activity was normalized to total
protein content, as determined by Bradford assay (Bio-Rad).
2.12. siRNA Knockdown of GPR109A in PC12 Cells.
PC12 cells in suspension (150,000 cells/ml) were transfected with 2.5 μg GPR109A siRNA
Flexitube Gene Solution or Allstars negative control siRNA (Qiagen, KY) using 12 μl HiPerFect
transfection reagent (Qiagen, KY) in 6 wells plates for 24 hrs according to the manufacturer’s
protocol. A substantial (≈70%) reduction in GPR109A expression (western blot) validated the
adopted siRNA knockdown strategy.
2.13. MTS Cell Viability Assay
PC12 cells were plated in 96-well plates and cultured for 48 hrs (100,000 cells/ml).
Different treatments were performed in serum free medium. In one experiment, the cells were
incubated with NA (100µm, 1mM and 10mM) or IsoNA (10mM) for 24 hrs. In another
experiment, cells were treated with NA (1mM) or PGE2 (10µM) with or without 30 min prior
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incubation with the EP3R blocker, L-798106 for 24 hrs. Twenty microliters of MTS reagent
(Promega, Madison, WI) was then added to each well following the manufacturer instructions
and absorbance which represents viable cells was measured at 495 nm.
CHAPTER THREE - Central GPR109A Activation Mediates Glutamate-Dependent
Pressor Response in Conscious Rats
3.1. Abstract
G protein-coupled receptor 109A (GPR109A) activation by its ligand nicotinic acid (NA) in
immune cells increases Ca2+ levels, and Ca2+ induces glutamate release, and oxidative stress in
central blood pressure (BP) regulating nuclei e.g. the rostral ventrolateral medulla (RVLM)
leading to sympathoexcitation. Despite NA ability to reach the brain, the expression and function
of its receptor GPR109A in the RVLM remains unknown. We hypothesized that NA activation
of RVLM GPR109A causes Ca2+ dependent L-glutamate release, and subsequently increases
neuronal oxidative stress, sympathetic activity, and BP. To test this hypothesis, we adopted a
multilevel approach, which included pharmacological in vivo studies along with ex vivo and in
vitro molecular studies in PC12 cells (exhibit neuronal phenotype). We present the first evidence
for GPR109A expression in the RVLM and in PC12 cells. Next, we showed that RVLM
GPR109A activation (NA) caused pressor and bradycardic responses in conscious rats. The
resemblance of these responses to those caused by intra-RVLM glutamate, and their attenuation
by NMDA receptor (NMDAR) blockade (2-amino-5-phosphonopentanoic acid; AP5) and
enhancement by L-glutamate uptake inhibition (L-trans-Pyrrolidine-2,4-dicarboxylic acid; PDC)
supported our hypothesis. NA increased Ca2+, glutamate, nitric oxide (NO) and reactive oxygen
species (ROS) levels in PC12 cells and increased RVLM ROS levels. The inactive NA analog
iso-nicotinic acid (IsoNA) failed to replicate the cardiovascular and biochemical effects of NA.
Further, GPR109A knockdown (siRNA) abrogated the biochemical effects of NA in PC12 cells.
These novel findings yield new insight into the role of RVLM GPR109A in central BP control.
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3.2. Introduction
The recently identified G protein coupled receptor 109A (GPR109A) is now recognized as the
molecular target that mediates the long established anti-hyperlipidemic effect of nicotinic acid (NA)
(Canner et al., 1986; Carlson, 2005). The most common side effect of NA is the prostaglandins-
dependent flushing reaction (Andersson et al., 1977; Morrow et al., 1989). The latter involves
intracellular Ca2+ elevation and subsequent activation of phospholipase A2 (Lin et al., 1992; Benyo
et al., 2006). In the CNS, higher intracellular Ca2+ levels enhance neurotransmitters release,
including glutamate (Kish and Ueda, 1991; Berridge, 1998; Sudhof, 2004).
GPR109A is widely expressed in white and brown adipose tissue, keratinocytes and various immune
cells including monocytes, macrophages, neutrophils and dendritic cells including Langerhans cells
(Soga et al., 2003; Tunaru et al., 2003; Wise et al., 2003; Hanson et al., 2010), and likely in
microglia (Penberthy, 2009). Despite NA ability to enter the brain (Spector, 1979), there are no
reports on the expression or function of GPR109A in cardiovascular regulating nuclei including the
RVLM. The latter sends excitatory input to the sympathetic preganglionic neurons, and regulate the
sympathetic nervous system and peripheral cardiovascular activity (Ciriello et al., 1986; Chapp et
al., 2014).
Realizing that NA activation increases intracellular Ca2+ in other cell types (Benyo et al., 2006), it is
likely that access of NA to central GPR109A might produce a similar effect and triggers L-glutamate
release in the RVLM, which is Ca2+-dependent (Tingley and Arneric, 1990). L-glutamate activation
of fast-acting ionotropic receptors, including NMDA and AMPA receptors increases intracellular
Na+ and Ca2+ as well as nerve firing (Dingledine et al., 1999). While the L-glutamate activation of
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the central ionotropic or the metabotropic receptors (Gabor and Leenen, 2012) causes
sympathoexcitation and a pressor response (Ito et al., 2003), the NMDA receptor (NMDAR)-
mediated fast and brief pressor response prevails in the RVLM (Kubo et al., 1993). Further,
elevations in Ca2+ (Lipton and Rosenberg, 1994) and L-glutamate (Albrecht et al., 2010) levels lead
to oxidative stress, and the occurrence of the latter in the RVLM leads to sympathoexcitation and
pressor response (Nishihara et al., 2012).
In the present study, we tested the hypothesis that Ca2+-dependent L-glutamate release and oxidative
stress, triggered by NA activation of RVLM GPR109A, causes sympathoexcitation and a pressor
response. We adopted a multilevel approach, which included pharmacological cardiovascular studies
in conscious rats complemented with ex vivo and in vitro molecular studies. We conducted the
detailed molecular studies in vitro, because the tissue scarcity and the rapid onset of the NA-evoked
pressor response precluded conducting detailed ex vivo studies on RVLM tissue. Importantly,
differentiated PC12 cells, used in these studies, exhibit a sympathetic-neuron-like phenotype
(Greene, 1978; Penugonda et al., 2005). Following the first demonstration of GPR109A expression
in the RVLM and in PC12 cells, we investigated the effects of intra-RVLM NA, or its inactive
isomer iso-nicotinic acid (IsoNA), on BP and heart rate (HR) in conscious rats. Additional in vivo
studies were conducted in the presence of NMDAR blockade (2-amino-5-phosphonopentanoic acid;
AP5), non-NMDAR (AMPA/Kainate) blockade (6-cyano-7-nitroquinoxaline-2,3-dione; CNQX) or
L-glutamate uptake inhibition (L-trans-Pyrrolidine-2,4-dicarboxylic acid; PDC) in the RVLM. The
effects of these pharmacological interventions or GPR109A knockdown (siRNA) on the GPR109A
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(NA)-mediated biochemical responses were also investigated in PC12 cells to complement, and to
mechanistically explain, the in vivo findings.
3.3. Materials and Methods
3.3.1. Animal Preparation.
Male Sprague Dawley (SD) rats (320–370 g; Charles River Laboratories, Raleigh, NC)
were used in this study. All rats were housed two per cage in a room with a controlled
environment at a constant temperature of 23 ± 1°C, humidity of 50% ± 10%, and a 12-hour
light/dark cycle. Food (Prolab Rodent Chow, Prolab RMH 3000; Granville Milling, Creedmoor,
NC) and water were provided ad libitum. All surgical, postoperative care, and experimental
procedures were performed in accordance with, and approved by the Institutional Animal Care
and Use Committee and in accordance with the Guide for the Care and Use of Laboratory
Animals (Institute for Laboratory Animal Research, 2011). Surgical procedures, BP and HR
measurements were performed as reported in our recent study (Penumarti and Abdel-Rahman,
2014), and as detailed in chapter 2.
3.3.2.   Cell Culture
Rat neuronal pheochromocytoma cell line (PC12 cells) was purchased from ATCC
(Rockville, MD). Cells were grown in F12k medium supplemented with horse serum (15%),
fetal bovine serum (2.5%), penicillin (100U/ml), and streptomycin (100U/ml) at 37°C in a
humidified incubator with 95% air and 5% CO2. The cells were cultured on corning cell bind
flasks for proper adherence followed by treatment with nerve growth factor (50ng/ml) till
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completely differentiated to the neuronal phenotype according to the protocol of the supplier.
Passage was done every 3-5 days when cells reach confluence as in our previous studies (Zhang
et al., 2001).
3.3.3. Western Blot Analysis and Immunofluorescence.
We followed the protocols described in chapter 2 and in our previous studies (Ibrahim and
Abdel-Rahman, 2012; Penumarti and Abdel-Rahman, 2014).
3.3.4. (Ca2+)i, Glutamate, and NO Measurements.
(Ca2+)i was measured in PC12 cells using cell permeant fura-2 AM (1 μM) (Molecular
Probes, Invitrogen) as detailed in chapter 2.  For L-glutamate measurement, Amplex Red kit was
used (Molecular Probes, Invitrogen) following the manufacturer instructions and reported studies
(Medina-Ceja et al., 2015) as provided in chapter 2. NO was measured using 4-amino-5-
methylamino-2′,7′-difluorofluorescein diacetate (DAF-FM Diacetate) (Molecular Probes, Grand
Island, NY) according to the manufacturer instructions and reported studies (Cortese-Krott et al.,
2012) as described under methods in chapter 2.
3.3.5. Measurement of Oxidative Stress.
We used 2′,7′-Dichlorofluorescein diacetate (DCFH-DA) (Molecular Probes, Grand Island,
NY), a general detector of oxidative species, to measure oxidative stress in PC12 cells and in
RVLM specimens taken from animals that received NA or its vehicle. Further, the
dihydroethidium (DHE) staining method, which is more superoxide anion selective (Bindokas et
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al., 1996; Robinson et al., 2006) was used for ROS measurements in RVLM sections of animals
that received the different treatments described below. The methods and protocols used are
detailed in our previous studies (Penumarti and Abdel-Rahman, 2014) and described in chapter
2.
3.3.6. siRNA Knockdown of GPR109A in PC12 Cells.
PC12 cells in suspension (150,000 cells/ml) were transfected with 2.5 μg GPR109A siRNA
Flexitube Gene Solution or Allstars negative control siRNA (Qiagen, KY) using 12 μl HiPerFect
transfection reagent (Qiagen, KY) in 6-wells plates for 24 h according to the manufacturer’s
protocol. A substantial (≈70%) reduction in GPR109A expression (western blot) validated the
adopted siRNA knockdown strategy.
3.4. Experimental Groups and Protocol
3.4.1. Experiment 1: Expression of GPR109A in the RVLM and PC12 Cells.
The objective of this experiment was to determine if GPR109A is expressed in the RVLM
and in PC12 cells, and its spatial distribution in the RVLM relative to different cell types,
particularly tyrosine hydroxylase (TH) immunoreactive (ir) neurons, which modulate the
sympathetic activity and BP (Guyenet, 2006a; Kumagai et al., 2012). First, western blot (WB)
analysis was conducted to detect GPR109A in PC12 cell lysate, and in punches taken from the
RVLM of naïve rats (n = 3).  Tissues rich in (spleen), or devoid of (liver) GPR109A (Soudijn et
al., 2007) were used as positive and negative controls, respectively, in these studies. Second, dual
labeled immunofluorescence (IF) was conducted in post-fixed sections from rat frozen brains and
34
PC12 cells. Neuronal and glial cell markers including the neuronal marker, NeuN, the astrocyte
marker, GFAP, and the microglia marker, CD11b/c were used to investigate the spatial
distribution of GPR109A in different cell types in the RVLM. Further the expression of
GPR109A relative to TH-ir neurons was investigated by using an anti-tyrosine hydroxylase
antibody. We followed methods described in our previous studies (Ibrahim and Abdel-Rahman,
2011; Penumarti and Abdel-Rahman, 2014) and detailed in chapter 2.
3.4.2. Experiment 2: Functional Role of RVLM GPR109A in BP and HR Regulation.
As there are no reported studies on intra-RVLM NA, a preliminary study was conducted to
determine the optimal NA dose to be used throughout the study based on estimated penetration
of systemic NA into the CNS (Spector, 1979).  Two groups of conscious unrestrained SD rats (n
= 4-7), instrumented for BP and HR measurements and RVLM microinjections as detailed under
methods, received intra-RVLM NA (5, 10 and 20 μg/animal) or the vehicle, artificial
cerebrospinal fluid (ACSF). The 20 µg NA dose, which produced consistent pressor response,
was used in subsequent studies. There are currently no GPR109A antagonists. Therefore, to
ensure that the NA-evoked pressor response was GPR109A mediated, the same dose (20
μg/animal) of the NA inactive isomer, IsoNA, was microinjected into the RVLM of a third group
of rats (n = 6).
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3.4.3. Experiment 3: Effect of NMDAR, non-NMDAR Blockade or L-glutamate Uptake
Inhibition on the Cardiovascular Effects of NA.
The role of L-glutamate in NA-induced pressor response was investigated using different
pharmacological interventions in conscious male SD rats instrumented for measurements of BP
and HR and RVLM microinjections as detailed under methods. Four groups of rats (n = 5-7)
received the NMDAR blocker, AP5 (2 nmol/100nl) (Zhang and Abdel-Rahman, 2002a), the non-
NMDAR blocker, CNQX (200 pmol) (Wang et al., 2007), the glutamate uptake inhibitor, PDC
(1 µM) (Montiel et al., 2005) or ACSF 10 min before NA (20 μg/animal) microinjection.
3.4.4. Experiment 4: GPR109A-dependent Biochemical Effects of NA.
The objective of this experiment was to obtain direct biochemical evidence that GPR109A
mediates elevations in L-glutamate release, intracellular Ca2+ and reactive oxygen species (ROS),
which are implicated in sympathoexcitation and BP elevation (Lipton and Rosenberg, 1994; Ito
et al., 2003; Nishihara et al., 2012). PC12 cells, used as surrogates of RVLM neurons, were
incubated with NA (10 μM, 100 μM or 1mM) in the absence or the presence of the
pharmacological interventions used in vivo (experiment 3). This model system permitted rapid
(0.5-1 min) biochemical measurements after NA addition, a timeframe consistent with the rapid
onset of the pressor response caused by intra-RVLM NA. The dependence of the biochemical
effects of NA on GPR109A activation was verified in PC12 cells by: (i) replacing NA with its
inactive isomer, IsoNA (Maciejewski-Lenoir et al., 2006) (1 mM); (ii) the addition of NA (1
mM) to PC12 following GPR109A knockdown with siRNA (see methods). The pharmacological
interventions incubated with PC12 cells in the absence or the presence of NA (1 mM) included:
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(i) L-glutamate in a concentration (100 nM) that was achieved 1 min after NA (1 mM) addition
to PC12 (preliminary experiment); (ii) the glutamate uptake inhibitor, PDC (0.1 mM) for 1 h
(Pepponi et al., 2009); (iii) the NMDAR blocker, AP5 (100 μM) for 10 min (Reigada et al.,
2006). For ex vivo ROS measurements, brain tissues were collected from animals (n = 4–5 rats)
that received the different treatments following euthanasia with a lethal dose of pentobarbital
sodium (>100 mg/kg) at the end of BP recording period. Fresh unfixed brainstem sections (20
µm) sections were taken followed by collecting micropunches from the injected RVLM side
using a 0.75 micropunch instrument (Stoelting Co., Wood Dale, IL), using the following
coordinates 12.6 to -11.8 mm relative to bregma as in reported studies including ours (Paxinos et
al., 1980; Ibrahim and Abdel-Rahman, 2015).
3.4.5. Drugs.
NA, L-glutamate, and PDC were purchased from Sigma-Aldrich (St. Louis, MO), and DL-AP5
and CNQX from Tocris Bioscience (Ellisville, MO). Sterile saline was purchased from B. Braun
Medical (Irvine, CA). IsoNA acid was purchased from TCI America (Portland, OR).
3.5. Data Analysis and Statistics
Animal studies data (n = 3-7) and in vitro data from three independent experiments are
expressed as mean ± standard error of mean (S.E.M). Analysis of Variance (ANOVA) or
repeated-measures analysis of variance followed by Bonferroni’s post hoc test and Student's t-
test were carried out using GraphPad Prism to state differences between groups.
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3.6. Results
3.6.1. GPR109A Co-expression with Tyrosine Hydroxylase in the RVLM and in PC12 Cells.
WB analysis revealed and verified the expression GPR109A in the RVLM and PC12 cells,
when compared to tissues rich in (spleen) or devoid of (liver) GPR109A expression (Fig. 3.1A).
Further, dual-labeled IF findings in PC12 cells showed co-expression of GPR109A and TH (Fig.
3.1B). Cell type specific labeling (Fig. 3.2 A-D), and quantitative comparisons of cell types (Fig.
3.2E), showed that GPR109A is expressed in much greater percentage (approx. 70%) in neuronal
than in non-neuronal cells (astrocytes and microglia) (30%) of the counted cells in the RVLM
sections. Further, the majority (>90%) of the RVLM TH-ir neurons also expressed GPR109A
(Fig. 3.2E).
3.6.2. Activation of RVLM GPR109A Causes Glutamate-like Pressor Response and Neuronal
Oxidative Stress.
BP and HR values before intra-RVLM microinjection of NA in the absence or presence of
pharmacologic interventions, indicated below, were not significantly different (Table 1). Intra-
RVLM NA (5, 10, 20 µg) caused dose-dependent pressor response and bradycardia in conscious
rats (Fig. 3.3). These cardiovascular responses resembled the responses elicited by intra-RVLM
L-glutamate (1 nmol; 169 ng) (Fig. 3.3A). Importantly, the inactive NA isomer, IsoNA (20 µg),
failed to influence BP or HR (Fig. 3.4, A and B). Ex vivo studies revealed higher ROS levels in
NA (20 µg)-treated RVLM, but not following the same dose of IsoNA (Fig. 3.5).
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3.6.3. Selective NMDAR Blockade and Glutamate Uptake Inhibition Abrogates and Enhances,
Respectively, the Intra-RVLM NA-Evoked Oxidative Stress and Pressor Response.
Prior RVLM NMDAR (AP5; 2 nmol), but not non-NMDAR (CNQX; 200 pmol) blockade
abrogated (P < 0.05) the pressor and bradycardic responses (Fig. 3.4, C, D and E), and abolished
the increase in ROS (Fig. 3.5B) caused by subsequent intra-RVLM NA (20 µg).  On the other
hand, prior L-glutamate uptake inhibition with intra-RVLM PDC (1 µM) significantly (P < 0.05)
increased the magnitude and duration (presented as area under the curve, AUC) of the pressor
response (Fig. 3.4, C and E) and exacerbated the elevation in RVLM ROS (Fig. 3.5B) caused by
subsequent intra-RVLM NA (20 µg) microinjection. None of these intervention changed BP or
HR from the corresponding baseline values (Table 3.1).
3.6.4. GPR109A Activation Increases L-glutamate, Ca2+ and NO levels and Produces
NMDAR-Dependent Oxidative Stress in PC12 cells.
The rapid onset (approx. 1 min) of the pressor response caused by intra-RVLM NA
precluded measurements of RVLM L-glutamate, Ca2+ and NO levels during this timeframe.
Therefore, such measurements were made in differentiated PC12 cells, which exhibit neuronal
phenotype and express GPR109A (Fig. 3.1, A and B). NA (100 μM or 1mM) significantly (P <
0.05) increased Ca2+ (Fig. 3.6A), L-glutamate (Fig. 3.6B), and NO (Fig. 3.6C) levels 30-60 sec
after NA addition to the incubation medium. Pre-incubating PC12 cells with the L-glutamate
uptake inhibitor PDC (0.1 mM/1 h) significantly (P < 0.05) enhanced NA-evoked glutamate
release (Fig. 3.6B). These biochemical responses were associated with significant (P < 0.05)
increases in ROS levels (Fig. 3.7A). Notably, L-glutamate, in a concentration (100 nM), detected
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after NA (1 mM) addition to incubation medium (preliminary), significantly (P <0.05) increased
ROS level (Fig. 3.7B). Similar to ex vivo findings on RVLM (Fig. 3.5), the NA-induced
oxidative stress was circumvented by prior NMDAR blockade with AP5 (100 μM) (Fig. 3.7B).
Further, the inactive NA isomer, IsoNA (1 mM), had no effect on Ca2+, glutamate, NO (Fig. 3.6,
A, B and C) or ROS (Fig. 3.7A) levels.
3.6.5. GPR109A Knockdown Abolishes NA Induced Ca2+ and Glutamate Release in PC12
Cells.
There are no available GPR109A antagonists. Therefore, we used siRNA knockdown
strategy to validate the involvement of GPR109A in the NA-evoked biochemical responses in
PC12 cells, described above. The GPR109A targeting siRNA significantly (P < 0.05) reduced
GPR109A expression (Fig. 3.8A). In PC12 cells pretreated with the negative siRNA control
(scrambled siRNA), NA (1 mM) significantly (P < 0.05) increased Ca2+(Fig. 8B) and glutamate
(Fig. 3.8C) levels. However, in PC12 cells, which exhibited significant (P < 0.05) siRNA-
induced reduction in GPR109A expression (Fig. 3.8A), NA (1 mM) failed to produce these
biochemical responses (Fig. 3.8, B and C).
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Table 3. 1. Mean arterial pressure (MAP, mm Hg) and heart rate (HR, beats/min) values




Rats per group (n) MAP (mmHg) HR (beats/min)
ACSF 7 126.1 ± 5.501 341.7 ± 12.36
IsoNA 6 133.7 ± 4.219 336.3 ± 6.224
ACSF/Nicotinic acid 7 122.6 ± 5.086 353.7 ± 18.19
AP5/Nicotinic acid 5 127.2 ± 6.258 379.3 ± 26.75
PDC/Nicotinic acid 7 125.0 ± 3.070 326.7 ± 30.92
CNQX/Nicotinic acid 5 126.8 ± 4.737 340.2 ± 24.97
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Figure 3.1. Expression of GPR109A in the rat RVLM and PC12 cells
(A) Expression of GPR109A (42 kDa) in the rat RVLM or PC12 cells compared with expression
in the spleen (positive control) and liver (negative control). Data are presented as integrated
density ratio of GPR109A to the corresponding GAPDH values (n = 3) and expressed as mean ±
S.E.M. (B) Dual-labeled IF of PC12 cells showing co-expression of GPR109A and TH.
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Figure 3.2. Spatial distribution of GPR109A in the RVLM
Confocal dual-labeled IF of post-fixed RVLM sections (n = 4-6) from naïve rats (n = 6) showing
the spatial distribution of GPR109A in neurons, TH-ir neurons, astrocytes and microglia. Dual-
channel images showing GPR109A (green) and one of the following markers (red):  NeuN (A),
TH (B), GFAP (C) or CD11b/c (D). In general, the 3 images for each section (A, B, C or D)
show the same field at different magnifications where the two smaller images showing staining
for different markers (e.g. A2 and A3) while the larger image (e.g. A1) shows the merged
staining for these two markers. The arrows illustrate co-labeled cells. Scale bar, 20 μm. (E)
quantitative analysis of A, B, C and D. Bar graph represents the total number of cells expressing
different markers (white) and the number of co-labeled cells of GPR109A with each marker
(black) in the examined RVLM sections (mean ± S.E.M). CD11b/c: microglia marker; GFAP:
astrocytes marker; NeuN: neurons marker; IF: immunofluorescence; RVLM: the rostral
ventrolateral medulla; TH: tyrosine hydroxylase.
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Figure 3.3. Effect of intra-RVLM NA on MAP and HR in conscious male rats
Representative mean arterial pressure (MAP) and heart rate (HR) responses caused by intra-
RVLM NA (20µg) or L-glutamate (169 ng) (A). Effect of intra-RVLM NA (5, 10, or 20 μg) on
MAP (B) and HR (C) in conscious male rats. Values are mean change from base line ± S.E.M, (n
= 4-7). *P < 0.05 vs. ACSF. ACSF: artificial cerebrospinal fluid; ΔHR: change in HR; ΔMAP:
change in mean arterial pressure; RVLM: the rostral ventrolateral medulla.
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Figure 3.4. Effect of NMDAR blockade or glutamate uptake inhibition on NA pressor
response
Time-course changes in mean arterial pressure (ΔMAP) (A) and heart rate (ΔHR) (B) evoked by
intra-RVLM NA or IsoNA (20 µg) compared with equal volume of ACSF in conscious male rats.
(C, D): time-course changes in ΔMAP and ΔHR evoked by intra-RVLM NA (20 µg) in
conscious male rats pretreated, 10 min earlier, with ACSF, NMDA receptor blocker (AP5, 2
nmol/100nl) or L-glutamate uptake inhibitor (PDC, 1 µM). (E) The area under the curve (AUC)
data generated from 20 min BP time-course values for different treatments. Data from AP5 (2
nmol/100nl) or PDC (1 µM) treated rats were not significantly different from the control values,
and are not shown for clarity. Values are mean change from base line ± S.E.M (n = 5-7). *P <
0.05 vs. ACSF values; #P < 0.05 vs. NA. ACSF: artificial cerebrospinal fluid; BP: blood
pressure; IsoNA: iso-nicotinic acid; RVLM: the rostral ventrolateral medulla.
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Figure 3.5. Effect of GPR109A activation on RVLM ROS levels and the impact of NMDAR
blockade or glutamate uptake inhibition in this response.
(A) DCFH-DA measured ROS levels in terms of relative fluorescence units (RFU) of produced
DCF in the RVLM after ACSF or NA (20 μg) injection. (B) Effect of ACSF, NA (20 μg), AP5 (2
nmol)/NA (20 μg), CNQx (200 pmol)/NA (20 μg), PDC (1 µM )/NA (20 μg) and isoNA (20 μg)
on RVLM ROS levels detected by DHE staining (visualized with confocal microscopy and
quantified using Zen Lite 2011 software). Values are mean ± S.E.M. (n = 4-5 rats). *P < 0.05 vs.
ACSF values; #P < 0.05 vs. NA. ACSF: artificial cerebrospinal fluid; IsoNA: iso-nicotinic acid;
NA: nicotinic acid; RVLM: the rostral ventrolateral medulla.
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Figure 3.6. Effect of NA on Ca2+, L-glutamate and NO levels in PC12 Cells
(A) Effect of NA (10 µM, 100 µM, and 1mM), or IsoNA (1mM) on Ca2+ levels in PC12 cells.
Measurements were done 30 secs, 2 and 4 min incubation time. Data representing Ca2+
concentration (µM) is expressed as mean ± S.E.M. (B) Effect of 1 min exposure of PC12 cells to
NA or IsoNA (1mM) on L-glutamate levels (folds increase of control) with or without 1 h prior
incubation with PDC (0.1 mM). (C) NO DAF-FM fluorescence intensity in PC12 cells incubated
with NA (10 µM, 100 µM, 1mM) or IsoNA (1mM) for 1 min. Data are expressed as mean ±
S.E.M. *P < 0.05 vs. control values; #P < 0.05 vs. PDC; ^P < 0.05 vs. NA. IsoNA: iso-nicotinic
acid; NA: nicotinic acid; NO: nitric oxide.
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Figure 3.7. Role of glutamate in NA-mediated ROS generation in PC12 cells
Effect of NA (10 µM, 100 µM, and 1mM), or IsoNA (1mM) on DCFH-DA measured ROS
generation in PC12 cells (folds increase from control). (B) Effect of NA (1mM) on DCFH-DA
measured ROS generation compared to glutamate (100nM) with or without 1 h or 10 min prior
incubation with PDC (0.1 mM), or AP5 (100 μM), respectively. Kinetic measurements were
recorded for 30 min following different treatments. Data are expressed as mean ± S.E.M. *P <
0.05 vs. control. IsoNA: iso-nicotinic acid; L-glut.: L-glutamate; NA: nicotinic acid.
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Figure 3.8. Effect of GPR109A knockdown on NA-mediated increase in and glutamate
levels in PC12 cells
Western blot for GPR109A in siRNA transfected cells compared to control (n = 3). Data are
presented as integrated density ratio of GPR109A to the corresponding β-actin values, and
expressed as mean ± S.E.M. Effect of vehicle or NA (1mM) on Ca2+ (B) and glutamate (C) levels
in PC12 cells pre-incubated for 24 hrs with either scrambled or GPR109A siRNA.
Measurements were done at 30 secs and 1 min incubation times for the measurements of Ca2+
and glutamate, respectively, and represented as fold increase from corresponding control. Data




In this study we tested the hypothesis that NA activation of RVLM GPR109A induces L-
glutamate (NMDAR)-dependent oxidative stress and sympathoexcitation/pressor response. We
focused on the RVLM because it mediates L-glutamate-dependent increases in sympathetic
activity and BP, and tonically regulates the peripheral vascular activity (Ciriello et al., 1986;
Bazil and Gordon, 1993; Chapp et al., 2014).
Our most important findings are: (i) the majority of RVLM neurons, and particularly the
TH-ir neurons, express GPR109A; (ii) intra-RVLM injection of the GPR109A agonist NA, but
not its inactive isomer (IsoNA) caused elevations in RVLM oxidative stress and BP, which
resembled glutamate-evoked responses; (iii) NMDAR blockade (AP5) and L-glutamate uptake
inhibition (PDC) abrogated and exacerbated, respectively, the NA-evoked increases in BP and
RVLM oxidative stress; (iv) NA, but not IsoNA, increased Ca2+, NO, glutamate, and ROS levels
in PC12 cells; (v) GPR109A knockdown (siRNA) abrogated the NA-evoked biochemical
responses in PC12 cells.
GPR109A, which serves as a receptor for NA (Soga et al., 2003; Tunaru et al., 2003), is
expressed in adipose tissue and immune cells (Soga et al., 2003; Maciejewski-Lenoir et al., 2006;
Penberthy, 2009). Under normal physiological conditions, the levels of the endogenous agonist
(β-hydroxybutyrate) or exogenous agonist (NA), when taken as a vitamin, might be lower than
the µM-mM concentration range needed to activate GPR109A (Taggart et al., 2005). However,
when used in much higher doses as anti-hyperlipidemic drug (Brown et al., 2001; Whitney et al.,
2005), such NA concentrations might be achieved. Further, despite evidence that NA is
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transported into the brain in appreciable concentrations following systemic administration
(Spector, 1979), there are no reports on GPR109A expression or function in neuronal structures,
which regulates sympathetic outflow and BP (e.g. RVLM). Here, we present the first evidence
that GPR109A is expressed in RVLM neurons, including the TH expressing neurons (Fig. 3.2, A
and B); the latter modulate the sympathetic activity and BP (Guyenet, 2006a; Kumagai et al.,
2012). These findings, which infer a cardiovascular role for GPR109A, were confirmed by
observing dose-related increases in BP following intra-RVLM NA microinjection in conscious
rats (Fig. 3.3B). The rapid onset of the NA-induced pressor response along with the associated
bradycardia were reminiscent of cardiovascular responses elicited by L-glutamate microinjection
into the same neuronal pool observed in a separate group of rats (Fig. 3.3A), and in reported
studies including ours (Bachelard et al., 1990; Mao and Abdel-Rahman, 1994). While the rapid
onset of the pressor response (Fig. 3.3A) precluded investigation of NA effect on RVLM L-
glutamate release, we adopted pharmacological approaches in vivo and direct biochemical
measurements in PC12 cells to support L-glutamate involvement in the NA-evoked
cardiovascular responses. It is imperative, nonetheless, to note that these cardiovascular
responses were mediated via NA activation of RVLM GPR109A because the inactive NA
isomer, IsoNA, failed to produce similar cardiovascular effects (Fig. 3.4, A and B).
We hypothesized that NA activation of GPR109A in the RVLM leads to Ca2+-dependent
L-glutamate release because: (i)  NA (10 µM-3 mM) mediates GPR109A dependent increase in
intracellular Ca2+ levels in macrophages and epidermal Langerhans cells (Benyo et al., 2005;
Benyo et al., 2006; Vanhorn et al., 2012; Gaidarov et al., 2013), (ii) Ca2+ triggers L-glutamate
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release (Kish and Ueda, 1991; Berridge, 1998; Sudhof, 2004), and (iii) elevated L-glutamate
levels cause oxidative stress (Wang et al., 2013b; Yang et al., 2014), sympathoexcitation (Chapp
et al., 2014), and ultimately BP elevation (Iwata et al., 1987; Bazil and Gordon, 1993).
Therefore, the RVLM GPR109A most likely mediates a glutamate-dependent
sympathoexcitation. Although the origin of NA-induced glutamate release in the RVLM remains
uncertain, the RVLM presympathetic neurons contribute, at least partly to this process because
they exhibit the highest GPR109A level in the RVLM (Fig. 3.2E), and their axonal varicosities
contain the glutamate transporter VGLUT2, and release glutamate (DePuy et al., 2013). Our in
vivo and ex vivo findings supported the L-glutamate hypothesis because local NMDAR blockade
(AP5) abrogated, while glutamate uptake inhibition (PDC) exacerbated, the pressor response
(Fig. 3.4) and RVLM oxidative stress (Fig. 3.5) caused by intra-RVLM NA.
Next, we leveraged the biological phenotype resemblance of the differentiated PC12
cells and RVLM neurons (Separovic et al., 1997; Zhang et al., 2001) to obtain direct evidence
that NA activation of GPR109A leads to L-glutamate and Ca2+ release. However, in the absence
of any reports on GPR109A expression in PC12 cells, it was important to determine if, similar to
the RVLM neurons, the receptor is expressed, and is spatially associated with TH, in this cell
line. Our WB and dual labeling IF (Fig. 3.1, A and B) confirmed our assumptions, and validated
the use of differentiated PC12 cells as an appropriate model system for studying the biochemical
events triggered by NA activation of GPR109A. We showed that NA causes increases in Ca2+
and L-glutamate levels in PC12 cells (Fig. 3.6, A and B) along with oxidative stress (Fig. 3.7A).
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It was important to determine if the GPR109A-mediated increase in glutamate release
(Fig. 3.6B) accounts for the oxidative stress (Fig. 3.7A) because the latter is implicated in
sympathoexcitation as discussed above. Our findings support this view because: (i) NA (1 mM)
and L-glutamate, in a concentration (100 nM) similar to that released by NA (1 mM), produced
comparable increases in oxidative stress in PC12 cells (Fig. 3.7B); (ii) L-glutamate uptake
inhibition augmented the NA-induced glutamate release (Fig. 3.6B). Although no GPR109A
antagonists are currently available, these effects are most likely GPR109A-dependent because
the inactive NA isomer IsoNA, whose microinjection into the RVLM had no effect on BP or
RVLM redox state (Figs. 3.4 and 3.5), also failed to reproduce NA-evoked biochemical effects in
PC12 cells (Figs. 3.6 and 3.7). The latter findings agree with reported studies in other model
systems (Maciejewski-Lenoir et al., 2006; Gaidarov et al., 2013). Equally important, NA failed
to increase Ca2+ or glutamate levels in PC12 cells following siRNA-evoked GPR109A
knockdown (Fig. 3.8), which provided direct evidence for GPR109A mediation of NA actions,
and support the in vivo findings, discussed above.
It is important to comment on the role of the NMDAR in mediating the biochemical and
pressor responses caused by NA activation of GPR109A. As discussed above, NA activation of
GPR109A leads to the release of L-glutamate, which activates ionotropic and metabotropic
glutamate receptors (Gabor and Leenen, 2012). The rapid onset of the NA-evoked pressor
response is consistent with L-glutamate activation of the NMDAR ionotropic receptors in the
RVLM (Kubo et al., 1993). This assumption was confirmed by the ability of the NMDAR
blocker AP5 (Fig. 3.4C), but not the non-NMDAR blocker CNQX (Fig. 3.4E), to abrogate the
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NA-evoked pressor response as well as oxidative stress (Fig. 3.5B). Further, NMDAR activation
by L-glutamate mediates a Ca2+/calmodulin-dependent nNOS-derived NO generation and
neurotoxicity (Garthwaite et al., 1988; Dawson et al., 1993). There is also evidence that NO is
involved in glutamate-mediated neurotransmission in different brain areas (Southam et al., 1991;
Montague et al., 1994) including the RVLM (Martins-Pinge et al., 1999). Additionally, the
nNOS-derived NO in the RVLM causes sympathoexcitation in reported studies including ours
(Martins-Pinge et al., 2007; Ibrahim and Abdel-Rahman, 2012). Therefore, It is likely that the
increased levels of NO by NA (0.01-1mM) in PC12 cells (Fig. 3.6C) levels, which agrees with a
reported finding in cultured endothelial cells treated with similar (0.5-2mM) NA concentrations
(Huang et al., 2012), is probably due to the activation of NMDAR, via GPR109A mediated
glutamate release. Notably, higher NO levels can contribute to RVLM oxidative stress via its
interaction with elevated superoxide levels, detected by DHE staining in the RVLM of NA
treated rats (Fig. 3.5B), to produce peroxynitrite radical (Beckman et al., 1990), which causes
dose-dependent transient excitatory responses when injected into the RVLM (Zanzinger, 2002).
Conversely, others reported that intra-RVLM injection of NO precursor or donor decreases
sympathetic nerve activity and BP (Kagiyama et al., 1997). Therefore, the possibility must be
considered that the GPR109A-mediated increase in NO levels could either contribute to, or
oppose, the pressor effect of intra-RVLM NA.
In conclusion, the present study presents the first evidence for GPR109A expression in
the RVLM, and its mediation of sympathoexcitation and elevation of BP via
glutamate/NMDAR-dependent mechanisms (Fig. 3.9).  The complementary pharmacologic and
63
biochemical findings clearly implicate the GPR109A in the observed responses. The present
pharmacological findings might have clinical relevance in situations where high doses of NA are
prescribed for the treatment of hyperlipidemia. Further, the present findings might have
pathophysiological ramifications, particularly in hypertension for two reasons. First, there is a
clear link between an exacerbated RVLM neuronal oxidative stress and the elevated BP in
hypertension (Wu et al., 2014). Second, compared to normotensive controls, activation of RVLM
NMDAR causes greater elevation in BP in spontaneously hypertensive rats (Lin et al., 1995).
Collectively, the present findings, along with these reported studies, highlight central GPR109A
as molecular target for the development of novel antihypertensive medications.
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Figure 3.9. Proposed GPR109A signaling in the RVLM
Suggested mechanisms for the GPR109A-mediated pressor response caused by nicotinic acid
(NA) microinjection into the RVLM. The sequence of events is based on the findings that: (i)
Intra-RVLM GPR109A activation (NA) increased blood pressure in conscious freely moving
rats (Fig. 3.3), and increased RVLM ROS levels (Fig. 3.5); (ii) NA increased Ca2+, glutamate
NO and ROS levels (Figs. 3.6 and 3.7) in PC12 cells, which exhibit a neuronal phenotype. The
dashed arrows indicate proposed signaling (see text for details).
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CHAPTER FOUR - PGE2-EP3 RECEPTOR SIGNALING IS CRITICAL FOR THE
CENTRAL GPR109A-MEDIATED PRESSOR RESPONSE IN CONSCIOUS RATS
4.1. Abstract
Nicotinic acid (NA) activation of the G protein-coupled receptor 109A (GPR109A) in immune
cells releases prostaglandins (PGs), and prostaglandin E2 (PGE2) activation of its EP3 receptor
(EP3R) in the CNS increases sympathetic activity and blood pressure (BP). Despite NA ability to
reach the brain, it is not known if PGE2 release and its activation of EP3R in the rostral
ventrolateral medulla (RVLM) contribute to the centrally-mediated pressor effect of NA
observed in our recent study. To test this hypothesis, we determined if the EP3R is expressed in
the RVLM, and if PGE2 release in the RVLM is involved in the pressor and autonomic
(sympathoexcitatory) responses elicited by intra-RVLM NA in conscious rats. Biochemical
measurements showed higher PGE2 levels, c-Fos expression, ERK1/2 and nNOS
phosphorylation along with oxidative stress in the RVLM of NA-treated rats. Further, PGE2
increased L-glutamate release in cultured PC12 cells. Selective pharmacological inhibition of
nNOS (Nω-propyl-l-arginine, NPLA) abolished the pressor response and the associated oxidative
stress caused by intra-RVLM NA. We present the first evidence that EP3R is expressed in the
RVLM and that the selective EP3R blocker L-798106 attenuated the NA-evoked pressor
response and the associated biochemical responses. These findings suggest an intermediary role
for PGE2-EP3R signaling in the GPR109A-mediated elevations of RVLM neuronal activity and
BP. Further, the findings yield new insight into the sympathoexcitatory role of RVLM EP3R.
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4.2. Introduction
Nicotinic acid (NA) is used for the treatment of dyslipidemia and prevention of
clinical cardiovascular diseases partly via a recently identified receptor, GPR109A. The most
common side effect of NA is the flushing reaction due to Ca2+-dependent release of different
prostaglandins (PGs) including prostaglandin I2 (PGI2), prostaglandin E2 (PGE2), and
prostaglandin D2 (PGD2) (Benyo et al., 2005). Intracerebroventricular (ICV) or PGE2
microinjection into the hypothalamic paraventricular nucleus (PVN) increases the
sympathetic outflow/plasma catecholamines and BP in rats, and these effects are not
observed with other PGs (Ando et al., 1995; Ariumi et al., 2002; Murakami et al., 2002;
Zhang et al., 2011). PGE2 also causes L-glutamate release in different CNS cell types (Bezzi
et al., 1998; Wang et al., 2015), and induces reactive oxygen species (ROS) generation via
activating NADPH Oxidase (NOX) (Wang et al., 2013a). Further, central (ICV) injection of
PGE2 or misoprostol, the prostaglandin EP receptor agonist, increases c-Fos, a marker of
neuronal activity, levels (Bullitt, 1990; Morgan and Curran, 1991) in different brain areas
(Lacroix et al., 1996; Zhang et al., 2011). However, there is currently no information on the
expression and function of EP receptors in one of the major cardiovascular regulating nuclei,
the RVLM.
Our previous findings (Rezq and Abdel-Rahman, 2015) showed that GPR109A is
expressed in tyrosine hydroxylase immunoreactive neurons (TH-ir) in the RVLM, and that its
activation by NA causes a pressor response in conscious rats. Pharmacologic and mechanistic
studies in PC12 cell line, which exhibits neuronal phenotype (Separovic et al., 1997), suggest
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local L-glutamate release in the robust pressor response caused by intra-RVLM NA in our
previous study (Rezq and Abdel-Rahman, 2015). However, it is not known if local PGE2
serves an intermediary role in the GPR109A (via NA)-mediated L-glutamate release in the
RVLM and the subsequently elicited pressor response.
Four subtypes of prostanoid receptors (EP1, EP2, EP3, and EP4) are known to
mediate the responses of PGE2 (Narumiya et al., 1999), among which EP3 receptor (EP3R)
mediates the central cardiovascular excitatory effects and renal sympathetic nerve activity of
PGE2 (Ariumi et al., 2002; Zhang et al., 2011). Notably, the reported EP3R-dependent
activation of ERK1/2 (Chuang et al., 2006; Nicola et al., 2008) could be an important
mediator of sympathetic excitation because ERK1/2 activation of nNOS-NO signaling in the
RVLM reduces GABA release and elicits sympathoexcitation (Chan et al., 2003; Martins-
Pinge et al., 2007). Despite this knowledge, the role of EP3R in central RVLM BP regulation
has not been investigated perhaps due lack of information on EP3R expression in the RVLM.
In the present study we tested the hypothesis that local PGE2 activation of EP3R
plays a pivotal role in the GPR109A-mediated glutamate release and the subsequent
biochemical events in the RVLM that ultimately produce the NA-evoked pressor response.
To test our hypothesis, it was important to determine if the EP3R is expressed in the RVLM
and in PC12 cells before conducting the pharmacological and molecular studies. In vivo
studies in conscious rats included investigations of the cardiovascular function of RVLM
EP3R, and the effect of its blockade (L-798106, 0.1 nmol/100nl), on the BP and autonomic
responses elicited by intra-RVLM NA (20 µg/rat). Molecular studies were conducted ex vivo,
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and in PC12 cells, to elucidate the roles of PGE2/EP3R-dependent increases in glutamate
release, RVLM neuronal/sympathetic activity (c-Fos expression, p-ERK1/2 and p-nNOS
levels), and oxidative stress (enhanced NOX and reduced catalase activities) as molecular
mechanisms for the RVLM GPR109A (NA)-mediated pressor response in conscious rats.
Parallel molecular studies on tissues collected following treatment with the inactive NA
isomer, IsoNA, were conducted to confirm the dependence of the observed molecular events
on GPR109A activation.
4.3. Materials and Methods
4.3.1. Animal Preparation.
Male Sprague Dawley (SD) rats (300–360 g; 12-13 weeks old; Charles River Laboratories,
Raleigh, NC) housed two per cage were used in this study. The rats were kept in a controlled
environment at a constant temperature of 23 ± 1°C, humidity of 50% ± 10%, and a 12-hour
light/dark cycle with food (Prolab Rodent Chow, Prolab RMH 3000; Granville Milling,
Creedmoor, NC) and water provided ad libitum. Surgical and experimental procedures were
performed in accordance with, and approved by the Institutional Animal Care and Use
Committee and in accordance with the Guide for the Care and Use of Laboratory Animals
(Institute for Laboratory Animal Research, 2011).
4.3.2. Surgical procedure.
Femoral artery catheterization and stereotaxic implantation of RVLM guide cannula were
performed under anesthesia (ketamine, 9 mg/100 g and xylazine 1 mg/100 g, i.p.) and
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appropriate analgesia (buprenorphine, 0.03 mg/kg) as detailed in our recent study (Rezq and
Abdel-Rahman, 2015). Histological verification of the RVLM position was done via intra-
RVLM injection of fast green dye (EM Sciences, Cherry Hill, NJ).
4.3.3. Blood Pressure and Heart Rate Measurements.
Five days after the surgical procedures, ML870 (PowerLab 8/30) system was utilized to
measure blood pressure (BP) and heart rate (HR) in conscious unrestrained rats. The data were
analyzed and displayed using LabChart (v. 7) pro software (AD Instruments, Colorado Spring,
CO) as in our reported studies (Ibrahim and Abdel-Rahman, 2011; Nassar et al., 2011; Penumarti
and Abdel-Rahman, 2014).
4.3.4. Spectral Analysis and Heart Rate Variability Analysis.
Spontaneous baroreflex sensitivity (BRS) was measured by the frequency domain analysis
method as in reported studies including ours (Parati et al., 1995; Shaltout and Abdel-Rahman,
2005) using Nevrokard SA-BRS software package (Nevrokard SA-BRS; Medistar, Ljubljana,
Slovenia) for small animals. The Power of RR interval (RRI) and spectral density oscillations
computed for the two speciﬁc frequency bands, low frequency (LF, 0.25–0.75 Hz) and high
frequency (HF, 0.75–3 Hz) domains, which reflect changes in sympathetic and vagal activity,
respectively (Malliani et al., 1991) were used as indices for spontaneous BRS while the
sympathovagal balance index (LFRRI/HFRRI) was used as an index of heart rate variability (HRV).
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4.3.5. Cell Culture.
Rat neuronal pheochromocytoma cell line (PC12 cells) purchased from ATCC (Rockville,
MD) was used according to the protocol detailed in our recent study (Rezq and Abdel-Rahman,
2015).
4.3.6. Western Blot.
Protocols from our recent study (Rezq and Abdel-Rahman, 2015) were followed. For EP3R
expression, membranes were incubated with anti EP3R polyclonal antibody (1:500; Cayman,
Ann Arbor, MI) at 4°C overnight. The band was verified using EP3R blocking peptide (Cayman,
Ann Arbor, MI). For ERK1/2 and nNOS measurements, membranes were incubated overnight at
4°C with a mixture of rabbit anti-phospho-nNOS (Ser1417) antibody (1:500; Thermo Fisher
Scientific, Waltham, MA) or rabbit anti-ERK1/2 (1:500; Cell Signaling, Danvers, MA) and
mouse polyclonal anti-nNOS antibody (1:500; BD Biosciences, San Jose, CA) or mouse anti-
pERK1/2  (1:500; Cell Signaling, Danvers, MA). Membranes were washed four times with
phosphate-buffered saline (PBS) containing 0.1% Tween 20 then incubated for 60 min with
mixture containing IRDye680-conjugated goat anti-mouse and IRDye800-conjugated goat anti-
rabbit (1:5000; LI-COR Biosciences). Bands representing phosphorylated and total protein were
detected simultaneously by using Odyssey Infrared Imager and analyzed with Odyssey
application software version .3 (LI-COR Biosciences). Data represent mean values of integrated
density ratio of p-nNOS or p-ERK1/2 normalized to the corresponding total nNOS (t-nNOS) or
total ERK1/2 (t-ERK1/2), respectively.
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4.3.7. Immunofluorescence.
The protocol used in our recent report (Rezq and Abdel-Rahman, 2015) was used for TH-ir
neurons and c-Fos-ir neurons colocalization studies in coronal sections containing the RVLM,
rostrally from -12.8 to -11.8 mm relative to bregma (Paxinos et al., 1980). Frozen sections from
brains of treated and control rats (n = 5-7) were incubated for 48 h at 4°C in a mixture of mouse
anti-TH (1:200; EMD Milipore, Temecula, CA) and rabbit polyclonal anti-c-Fos antibody
(1:200; Santa Cruz Biotechnology, CA). The sections then were incubated for 2 h in a mixture of
Cy3-conjugated donkey anti-mouse and fluorescein isothiocyanate-conjugated donkey anti-
rabbit (1:200; Jackson Immunoresearch Laboratories Inc., West Grove, PA). A Zeiss LSM 510
confocal microscope (Carl Zeiss Inc., Thornwood, New York) was used for the visualization,
acquisition, and quantification of colocalization. Four to six sections per animal at the level of
RVLM were examined. Fluorescence intensity was quantified using Zen Lite 2011 software.
4.3.8. Measurement of PGE2.
PGE2 level in RVLM homogenates (10 µg protein/sample) or the culture media of PC12
cells was measured using rat PGE2 ELISA kit (Cayman, Ann Arbor, MI) according to the
manufacturer’s instructions. The absorbance was detected at 420 nm. A standard curve was
established using serial dilutions of PGE2 standard. Different samples PGE2 levels were
calculated from the standard curve equation.
73
4.3.9. NOX Activity.
NOX activity was measured according to reported protocols (La Favor et al., 2013) with
modification. For this assay, 30 μl of homogenate was added to 180 μl of a cocktail containing
10 μM Amplex Red (Molecular Probes, OR), 2.0 U/ml horseradish peroxidase, 30 U/ml
superoxide dismutase, and 100 μM NADPH (Sigma Aldrich, St. Louis, MO) in PBS.
Fluorescence intensity (530 nM ex/590 nM em) was measured continuously with a microplate
fluorescence reader at 37°C at 5 min intervals for 30 min, total NADPH-dependent H2O2
generated in the sample was used as an index of NOX activity. Activity was normalized to total
protein content, as determined by Bradford assay (Bio-Rad).
4.3.10. Catalase Activity.
RVLM punches from injected sites were homogenized in 35 μl lysis buffer (20 mM Tris,
pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium
pyrophosphate, 1 mM β-glycerol-phosphate, 1 mM activated sodium orthovanadate, and 1 μg/ml
leupeptin) with protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN) followed by
centrifugation at 14,000 rpm for 20 min at 4°C. The supernatant was separated and assayed for
protein content (Bradford assay, Bio-Rad). Catalase activity was determined colorimetrically in
10 μg protein using the Catalase Assay Kit (catalog no. CAT-100, Sigma-Aldrich, St. Louis,
MO) according to the manufacturer's instructions.
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4.3.11. DCFH-DA.
A 20 mM stock solution of 2′,7′-Dichlorofluorescein diacetate (DCFH-DA) (Molecular
Probes, Grand Island, NY) in methanol was prepared and kept at -20°C in the dark. RVLM
homogenate in PBS (50 mM, pH 7.4) from different groups was centrifuged at 14,000 rpm for 20
min at 4°C. The protein in the supernatant was quantified using a Bio-Rad protein assay system.
Shortly before the experiment, DCFH-DA stock solution was freshly diluted with PBS to 150
µM working solution. The reaction started by adding 10 µl RVLM homogenate supernatant in a
96-well plate for a final concentration of 25 µM DCFH-DA to generate fluorescent 2′,7′-
Dichlorofluorescein (DCF) followed by measuring fluorescence intensity using a microplate
fluorescence reader at excitation 485 nm/emission 530 nm for 60 min at 37°C . DCF was used to
generate the standard curve. Reactive oxygen species (ROS) level was expressed in terms of
relative fluorescence units (RFU) of produced DCF as detailed in our recent study (Rezq and
Abdel-Rahman, 2015).
4.3.12. L-glutamate Measurement
L-glutamate release in cultured PC12 cells was measured using Amplex Red kit (Molecular
Probes, Invitrogen) following the manufacturer instructions and as detailed in our recent study
(Rezq and Abdel-Rahman, 2015).
4.3.13. Protocols and Experimental Groups.
We investigated the effects of prior RVLM EP3R blockade (L-798106, 0.1 nmol) on BP,
HR and autonomic responses elicited by intra-RVLM NA (20 μg). It was important to determine,
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for the first time, the dose of L-798106 that optimally block the RVLM EP3R in a pilot study (n
= 3). The selected intra-RVLM PGE2 dose (0.2 nmol), which produced pressor response when
injected into the hypothalamus (Zhang et al., 2011), also produced pressor response that was
abolished by the selected L-798106 dose in our pilot study. Conscious unrestrained SD rats (n =
5-8 each), pre-instrumented with intra-RVLM and intra-arterial cannulas as indicated under
methods, were used. BP and HR were allowed to stabilize at baseline, for at least 30 min, before
intra-RVLM microinjections started. All injections (100 nl) were made unilaterally into the
RVLM according to established protocol in our lab (Penumarti and Abdel-Rahman, 2014).
Control rats received 100 nl of the artificial cerebrospinal fluid (ACSF) that was used as a
vehicle. Treatment groups received L-798106 or the vehicle followed 10 min later by 100 nl of
NA (20 μg) or ACSF.  To investigate the role of nNOS in NA-mediated pressor response, the
selective nNOS blocker, Nω-propyl-l-arginine (NPLA, 250 pmol) was injected in a separate
group of rats followed by NA (20 μg) or equal volume of ACSF (n = 5 each). The selected
NPLA dose was used in our previous studies (Ibrahim and Abdel-Rahman, 2012). At the end of
BP recording period, animals were euthanized with a lethal dose of pentobarbital sodium
(100 mg/kg), and their brains were rapidly removed and stored at -80°C. For the different
biochemical measurements detailed above, a 0.75 micropunch instrument was used to collect
unilateral micropunches (Stoelting Co., Wood Dale, IL) at -12.8 to -11.8 mm relative to bregma
(Paxinos et al., 1980) from the injected RVLM site (n = 5-8). For in vitro EP3R expression
(WB), PGE2 and glutamate measurements, neuronal PC12 cells were used as surrogates of
RVLM neurons.  PGE2 ELISA measurement was performed in the media of cells treated with
NA (1mM) for 5 min. The effect of NA (1 mM) or PGE2 (10 μM) on glutamate release in treated
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cells was investigated with or without 30 min prior incubation with L-798106 (10 μM). To
investigate the role of nNOS in NA mediated L-glutamate release, PC12 cells were pretreated
with NPLA (1 μM) for 30 min according to reported protocol (Filpa et al., 2015). For each
experiment, IsoNA (20 μg in rats or 1mM in cells), the inactive isomer of NA that lack
GPR109A activity (Maciejewski-Lenoir et al., 2006), was used to verify the dependence of the
effect on GPR109A. The tissues used for ex vivo biochemical measurements following intra-
RVLM IsoNA (20 μg) came from rats used in our recent study (Rezq and Abdel-Rahman, 2015).
4.4. Drugs
NA and L-798106 were purchased from Sigma-Aldrich (St. Louis, MO). PGE2 was purchased
from Cayman (Ann Arbor, MI). Sterile saline was purchased from B. Braun Medical (Irvine,
CA). IsoNA acid was purchased from TCI America (Portland, OR). NPLA was purchased from
Abcam (Cambridge, MA).
4.5. Statistical Analysis
In vitro data were collected from three independent experiments, and in vivo data were
collected from 3-8 rats per group. Data are expressed as mean ± standard error of mean (S.E.M).
Analysis Of Variance (ANOVA) or repeated-measures ANOVA followed by Bonferroni’s post




4.6.1. EP3R is Expressed in the RVLM and PC12 Cells.
EP3R was expressed in the RVLM and in PC12 cells (Fig. 4.1A), and the bands were
verified using EP3R blocking peptide (Fig. 4.1B) as well as by including blot from the kidney as
positive control (Kotani et al., 1995). Notably, the molecular weight of EP3R varies from 53-98
kDa (Fig. 4.1A) according to the degree of its posttranslational modification, and whether the
receptor is expressed as monomer or dimer (Osborne et al., 2009).
4.6.2. GPR109A Activation via NA Increases PGE2 Levels in the RVLM and in PC12 Cells.
Although a number of studies reported NA to increase PGE2 levels by activating peripheral
GPR109A receptor, there is no evidence for NA ability to produce a similar effect centrally.
Therefore, PGE2 measurements were done in the RVLM of NA-treated rats (20 µg, n = 6-8) and
in PC12 cells incubated with NA (1 mM, n = 3). NA caused approximately two-fold increase in
PGE2 levels, compared to vehicle treatment in both preparations (Fig. 4.1C, D). This effect is
likely GPR109A receptor-dependent because the inactive NA isomer, IsoNA, did not change
PGE2 levels in both preparations (Fig. 4.1C, D).
4.6.3. Central PGE2/EP3R Signaling Mediates the Pressor and Autonomic Responses
Elicited by Intra-RVLM NA.
Due to the lack of data on the cardiovascular effects of intra-RVLM PGE2 or the EP3R
blocker, we used a PGE2 dose (0.2 nmol), which produced sympathoexcitation following
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microinjection into the hypothalamus (Zhang et al., 2011), in the absence or presence of the
EP3R antagonist, L-798106 (0.1 nmol). Intra-RVLM PGE2 caused modest but significant (P <
0.05; n=3) increase in BP, which was fully abrogated by prior EP3R blockade by L-798106 (0.1
nmol/100nl; n = 5) (Fig. 4.2A). Similarly, prior EP3R blockade significantly (P < 0.05)
attenuated the pressor and bradycardic responses caused by intra-RVLM NA (20 µg; n = 8) (Fig.
4.2C and D). The significant (P < 0.05) increase in LF/HF ratio, caused by intra-RVLM NA
(indicative of increased sympathetic dominance) was abrogated by prior EP3R blockade (Fig.
4.3); neither EP3 blockade nor IsoNA had any effect on the measured variables (Data not
shown). Moreover, there were no significant differences between the BP and HR values of all
groups prior to drug or vehicle administration (Table 1).
4.6.4. EP3R Mediates the NA-Evoked Increase in Glutamate Levels.
Our previous in vivo and PC12 cell findings (Rezq and Abdel-Rahman, 2015) confirmed
the contribution of L-glutamate release to the intra-RVLM NA-mediated pressor response. The
purpose of this experiment was to investigate the role of EP3R in L-glutamate release and in the
pressor response elicited by intra-RVLM NA or PGE2 (Fig. 4.2). NA (1 mM) or PGE2 (10 µM)
significantly (P < 0.05) increased glutamate level in cultured PC12 cells, and such response was
virtually abolished by prior incubation with the selective EP3R blocker L-798106 (10 µM) (Fig.
4.4).
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4.6.5. Intra-RVLM GPR109A Activation Produces EP3R-Dependent Increase in c-Fos
Expression in RVLM TH-ir Neurons.
In this experiment, we investigated whether GPR109A (NA)-evoked increase in c-Fos
expression in RVLM TH-ir neurons (reflects sympathoexcitation) is EP3R-dependent.
Immunofluorescence staining of RVLM sections taken from animals that received different
treatments revealed that, compared to the vehicle, intra-RVLM NA (20 µg), but not IsoNA (20
µg), significantly (P < 0.05) increased c-Fos expression in the RVLM TH-ir neurons (Fig. 4.5).
Further, prior RVLM EP3R blockade (L-798106; 0.1 nmol/100nl) abrogated the increase in c-
Fos expression in the RVLM TH-ir neurons caused by intra-RVLM NA (20 µg) (Fig. 4.5D). The
total numbers of TH-ir neurons in the control and treatment groups were similar (Fig. 4.5, lower
panels).
4.6.6. EP3R Blockade Abrogated the Increases in RVLM ERK1/2 and nNOS
Phosphorylation and NOX Activity and the Decrease in Catalase Activity Caused by
Intra-RVLM NA.
NA (20 μg; n = 5), compared to its vehicle (n = 6), significantly (P < 0.05) increased
RVLM ERK1/2 and nNOS phosphorylation (Fig. 6), NOX activity along with reducing catalase
activity, and these responses were associated with increased RVLM ROS level (Fig. 4.7). These
biochemical responses were mediated by NA activation of GPR109A because they were absent
in IsoNA treated rats (Figs. 4.6 and 7), and were EP3R-dependent because they were abrogated
by prior EP3R blockade with L-798106 (0.1 nmol/100nl) in NA-treated rats (Figs. 4.6 and 7).
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4.6.7. Inhibition of RVLM nNOS Attenuated GPR109A-Mediated Oxidative Stress and
Pressor Response.
The objective of this experiment was to establish a causal role for nNOS activation in
central GPR109A-mediated RVLM oxidative stress and pressor response. Prior intra-RVLM
injection of the selective nNOS inhibition NPLA (250 pmol) abrogated (P<0.05) the pressor and
bradycardic effects (Fig. 4.8A-C) and the increases in nNOS phosphorylation (Fig. 4.8D), ROS
(Fig. 4.8E) and NOX (Fig. 4.8F) as well as the reduction in catalase activity (Fig. 8G) caused by
intra-RVLM NA (20 μg; n = 5). Notably, NPLA significantly (P<0.05) inhibited nNOS
phosphorylation (Fig. 4.8E) and modestly (P<0.05) reduced ROS level (Fig. 4.8F) in the RVLM
but had no effect on the other biochemical or cardiovascular variables measured in this
experiment (Fig. 4.8).
4.6.8. Inhibition of nNOS Attenuated GPR109A-Mediated L-glutamate Release in PC12 cells
and c-Fos Induction in RVLM.
Prior incubation of the selective nNOS inhibition NPLA (1 µM) abrogated (P<0.05) NA-
mediated L-glutamate release in PC12 cells (Fig. 4.9A). Moreover, Prior intra-RVLM injection
of NPLA (250 pmol) protected NA-treated rats from increased c-Fos expression, the marker of
neuronal excitability (Fig. 4.9B).
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Table 4. 1. MAP (mmHg) and HR (beats/min) values before pharmacological intervention.
Values of Mean Arterial Pressure (MAP, mmHg) and Heart Rate (HR, beats/min) at the end of




Rats per group (n) MAP (mmHg) HR (beats/min)
ACSF 7 126.1 ± 5.501 341.7 ± 12.36
ACSF/Nicotinic acid 8 114.9 ± 5.266 366.5 ± 28.50
ACSF/PGE2 3 115.3 ± 5.365 415.4 ± 14.88
L-798106 /PGE2 3 124.0 ± 5.033 360.1 ± 4.167
L-798106 /Nicotinic acid 5 128.0 ± 7.406 335.0 ± 8.630
ACSF/NPLA 5 114.2 ± 2.46 347.8 ± 15
NPLA/NA 5 111.6 ± 4.65 326.9 ± 11.98
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Figure 4.1. EP3R expression in the RVLM and PC12 cells and NA ability to increase PGE2
levels in both preparations
(A) Expression of EP3R (53-98 kDa) in the rat RVLM, PC12 cells or kidney (positive control);
the wide range in molecular weight is ascribed to the different forms of the receptor (Osborne et
al., 2009). The lower panel shows expression of EP3R (53-98 kDa) in the rat RVLM, PC12 cells
or kidney (positive control). EP3R primary antibody was pre-incubated with its blocking peptide.
Data are presented as integrated density ratio of GPR109A to the corresponding β-actin values (n
= 4) and expressed as mean ± S.E.M. (B) Effect of NA (1 mM), or IsoNA (1 mM) on PGE2
levels (folds of control) in PC12 cells (n = 3 independent experiments). Measurements were done
after 5 min incubation time. (C) RVLM PGE2 concentration (pg/ml) following intra-RVLM
ACSF (100 nl; n = 6), NA (20 μg; n = 8) or IsoNA (20 μg; n = 5) injection. Data are expressed as
mean ± S.E.M. *P < 0.05 vs. control or ACSF values; #P < 0.05 vs. NA.
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Figure 4.2. Effect of intra-RVLM NA or PGE2 on MAP and HR with or without EP3R
blockade
Time-course changes in MAP and HR caused by intra-RVLM PGE2 (0.2 nmol, n = 3) (A, B) or
NA (20 µg; n = 8) (C, D), compared with equal volume of ACSF, in conscious male rats
pretreated, 10 min earlier, with ACSF (100 nl; n = 8) or EP3R blocker (L-798106, 0.1
nmol/100nl; n = 3-8). (E, F) The area under the curve (AUC) data generated from A and C,
respectively for different treatments. Data from L-798106 treated rats, which were not
significantly different from the control values, are not shown for clarity. Values are mean change
from base line ± S.E.M. *P < 0.05 vs. ACSF values; #P < 0.05 vs. NA. ACSF: artificial




Figure 4.3. Autonomic changes elicited by intra-RVLM NA injection with and without
prior EP3R blockade
Effect of intra-RVLM NA (20 µg; n = 6) or equal volume of ACSF (100 nl; n = 6) on: (A) low
frequency (LF) component of spectral analysis of RRI (0.25 to 0.75 Hz), index of cardiac
sympathetic tone; (B) High frequency (HF) component of the spectral analysis of RRI (0.75 to 3
Hz), index of cardiac vagal tone, and (C) LFRRI/HFRRI ratio as a measure of sympathovagal
balance in conscious male rats pretreated, 10 min earlier, with ACSF (100 nl; n = 6) or EP3R
blocker (L-798106, 0.1 nmol; n = 5). Data represent AUC values generated over the 30 min BP
recording period. Values are mean ± S.E.M.  *P < 0.05 versus ACSF values; #P < 0.05 vs. NA.
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Figure 4.4. Effect of intra-RVLM NA or PGE2 on glutamate release in PC12 cells (role of
EP3R)
Effect of 1 min exposure of PC12 cells to PGE2 (10 μM) or NA (1 mM) on L-glutamate levels
(folds increase of control) with or without 30 min prior incubation with the EP3R receptor
antagonist L-798106 (10 μM). Data are expressed as mean ± S.E.M of 3 independent
experiments. *P < 0.05 vs. control values; #P < 0.05 vs. NA; ^P < 0.05 vs. PGE2 values.
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Figure 4.5. Effect of NA on c-Fos intensity and its co-localization with TH
Confocal dual-channel images showing TH-ir neurons (red) and c-Fos immunoreactive cell
nuclei (green) in RVLM of rats treated as described under Materials and Methods with intra-
RVLM ACSF (A), 20 μg of isonicotinic (IsoNA; B), 20 μg of nicotinic acid (NA; C) or 0.1 nmol
of the EP3R blocker L-798106 + 20 μg of NA (D). In general, the 3 images for each section (A,
B, C, or D) show the same field at different magnifications where the two smaller images show
staining for different markers (e.g. A1 and A2) while the larger image (e.g. A) shows the merged
staining for these two markers. The arrows illustrate co-labeled cells. Scale bar, 20 μm. c-Fos
fluorescence intensity, number of TH-ir neurons, and percentage of TH-ir neurons colocalized
with c-Fos in the RVLM of control rats and treated rats are shown below. Bar graphs represent
mean ± S.E.M. of data obtained from four to six coronal brainstem sections/animal (n = 5-7
rats/group) by using one-way ANOVA followed by Bonferroni comparison test. *P < 0.05 vs.
ACSF values; #P < 0.05 vs. NA.
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Figure 4.6. Effect of NA on pERK1/2 and p-nNOS levels
Changes in rat RVLM ERK1/2 (A) and nNOS (B) phosphorylation following intra-RVLM  NA
(20 μg) or ACSF in animals pretreated with ACSF or the EP3R antagonist L-798106 (0.1 nmol).
Data are presented as integrated density ratio of phosphorylated (p-ERK1/2) or (p-nNOS) to the
corresponding total (t-ERK1/2) or (t-nNOS) protein, respectively. Values are mean ± S.E.M. of
5–6 observations/group. *p < 0.05 versus vehicle values, #P < 0.05 vs. NA.
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Figure 4.7. Effect of EP3R blockade on NA-mediated ROS generation and NOX and
catalase activities in the RVLM.
(A) DCFH-DA measured ROS levels in terms of relative fluorescence units (RFU) of produced
DCF in the RVLM (n = 5-6 rats) after ACSF (100nl), NA (20 μg), IsoNA (20 μg) or L-798106
(0.1 nmol)/ NA (20 μg). (B) Effect of ACSF (100nl), NA (20 μg), IsoNA (20 μg) or L-798106
(0.1 nmol)/NA (20 μg) on RVLM (n = 5-8 rats) NOX activity presented as the concentration of
produced H2O2 (μM/μg protein). (C) Effect of ACSF (100nl), NA (20 μg), IsoNA (20 μg) or L-
798106 (0.1 nmol)/ NA (20 μg) on RVLM (n = 4-6 rats) catalase activity (μmoles/μg
protein/min). Values are mean ± S.E.M. *P < 0.05 vs. ACSF values; #P < 0.05 vs. NA. ACSF:




Figure 4.8. Effect of intra-RVLM nNOS inhibition on GPR109A mediated pressor response
and oxidative stress
Changes in (A) Mean arterial pressure (ΔMAP), and (B) Heart rate (ΔHR) following intra-
RVLM microinjections of NA (20 μg) or equal volume of vehicle in conscious male SD rats
pretreated, 30 min earlier, with NPLA (selective nNOS inhibitor; 250 pmol). Pretreatment with
NPLA, virtually abolished the GPR109A (NA)-mediated pressor response. (C) Depict the area
under the curve (AUC) data generated from the time-course values over the treatment (30 min)
periods. (D) Inhibition of nNOS phosphorylation in ACSF and NA rats pretreated with NPLA
(250 pmol). Effect of prior NPLA treatment (250 pmol) on ROS levels (E), NOX activity (F) or
catalase activity (G) in rats pretreated with NA (20 μg) or equal volume of vehicle; n = 5 for all
groups. *P < 0.05 vs. ACSF (vehicle); #P < 0.05 vs. NA.
98
99
Figure 4.9. Effect of intra-RVLM nNOS inhibition on GPR109A mediated increase in L-
glutamate release and c-Fos intensity.
(A) Effect of prior NPLA treatment (1μM) on NA-mediated L-glutamate release (1 min
treatment) in cultured PC12 cells. (B) Effect of prior NPLA treatment (250 pmol) on c-Fos
intensity in rats pretreated with NA (20 μg) or equal volume of vehicle; n = 5 for all groups. *P <




In this study we tested the hypothesis that PGE2 (EP3R)-dependent elevations in
mediators of oxidative stress and presympathetic neuronal activity play a pivotal role in
RVLM GPR109A (NA)-mediated pressor response. Our most important findings are: (i)
intra-RVLM NA or PGE2 caused a pressor response in conscious rats; (ii) NA elevated
PGE2 (RVLM and PC12 cells), L-glutamate levels (PC12 cells), RVLM p-ERK1/2 and p-
nNOS levels as well as RVLM TH-ir neurons excitation (c-Fos); (iii) NA induced RVLM
oxidative stress due to increased NOX activity/ROS level and reduced catalase activity; (iv)
EP3R blockade (L-798106) or nNOS inhibition (NPLA) attenuated the NA-evoked increases
in BP and RVLM oxidative stress along with the associated biochemical responses. These
findings establish a sympathoexcitatory role for PGE2-EP3R signaling in the RVLM, and
present evidence for its contribution to the GPR109A-mediated RVLM oxidative stress and
pressor response, at least partly, via nNOS activation.
NA, which serves as a GPR109A receptor ligand (Soga et al., 2003; Tunaru et al.,
2003), produces a flushing reaction due to Ca2+-dependent release of different PGs including
PGE2 (Benyo et al., 2005). Therefore, aspirin is usually prescribed for patients who receive
NA for the treatment of hyperlipidemia (Andersson et al., 1977). We based our hypothesis on
evidence that systemic NA reaches the brain in appreciable concentrations (Spector, 1979),
the expression of the NA receptor, GPR109A, and its sympathoexcitatory function in the
RVLM (Rezq and Abdel-Rahman, 2015), and on the ability of ICV or intra-PVN PGE2 to
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increase sympathetic activity and BP (Ando et al., 1995; Ariumi et al., 2002; Murakami et
al., 2002; Zhang et al., 2011).
In our recent study (Rezq and Abdel-Rahman, 2015), intra-RVLM NA produced a
glutamate-dependent increase in BP that was associated with oxidative stress, but that study
focused on the initial (1-5 min) pressor response. The purpose of the current study was to
investigate whether PGs, particularly PGE2 release, contributes to longer lasting (30 min)
pressor response caused by RVLM GPR109A activation given PGE2 ability to induce
glutamate release (Bezzi et al., 1998; Wang et al., 2015).
While there is growing interest in the central effects of PGs, particularly the PGE2-
mediated sympathoexcitation via EP3R activation (Ariumi et al., 2002; Zhang et al., 2011;
Ando et al., 2015), the exact molecular mechanisms involved in this action are not clear.
Equally important, the possibility has not been considered that PGE2-EP3R signaling is
functional in the RVLM and contributes to the RVLM GPR109A-mediated pressor response.
We reasoned that if PGE2 ability to increase NOX activity (Wang et al., 2013a), c-Fos
expression and ERK1/2 pathway activation (Chuang et al., 2006) in different brain areas
(Lacroix et al., 1996; Zhang et al., 2011), extends to the RVLM, may uncover a new role for
PGE2 in the RVLM. Notably, these molecular mechanisms lead to sympathoexcitation and
BP increase (Chalmers et al., 1994; Minson et al., 1994; Ibrahim and Abdel-Rahman, 2012;
Chen et al., 2013). Therefore, we utilized a multilevel experimental approach to investigate
these novel and interrelated possibilities.
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In the absence of any data on the RVLM PGE2 or EP3R modulation of BP, it was
important to obtain the first evidence that the EP3R is expressed in the RVLM as well as in
the in vitro surrogate cell line, PC12 cells (Fig. 4.1A). Thereafter, we showed, for the first
time, that the pressor response caused by PGE2 (0.2 nmol) microinjection into the
hypothalamic pressor area (Zhang et al., 2011) is replicated in the RVLM, and is EP3R-
dependent because it was abrogated by the selective EP3R antagonist L-798106 (0.1 nmol)
(Fig. 4.2). Next, the significant (2-fold) elevations in PGE2 caused by NA in the RVLM and
PC12 cells (Fig. 4.1C and D) presented direct link between RVLM GPR109A and local PGs.
Two findings confirmed that the increase in RVLM PGE2 release was GPR109A-dependent
and that the released PGE2 mediated the NA-evoked pressor response, at least partly, via
local EP3R activation. First, the same intra-RVLM dose of the inactive NA isomer IsoNA
failed to increase PGE2 release (Fig. 4.1). Second, intra-RVLM L-798106 abrogated the
pressor response (time-course and AUC) caused by intra-RVLM NA (Fig. 4.2).
Whether L-glutamate release constitutes a biochemical link between NA and PGE2
deserved investigation because the GPR109A-dependent glutamate release, observed in
PC12 cells, explains, at least partly, the pressor response caused by intra-RVLM NA in our
recent study (Rezq and Abdel-Rahman, 2015). Here, we showed that NA increased PGE2
release in RVLM and in PC12 cells (Fig. 4.1), and increased glutamate release in PC12 cells
via a PGE2-EP3R dependent mechanism (Fig. 4.4). These novel findings supported our
hypothesis and further verified the relevance of the biochemical findings generated in PC12
cells in our present and recent studies (Rezq and Abdel-Rahman, 2015). The present findings
104
are consistent with PGE2 ability to: (i) Ca2+-dependently increase glutamate levels in
cultured astrocytes and neurons (Bezzi et al., 1998; Wang et al., 2015); (ii) enhance
glutamatergic neurotransmission in primary micro-cultures of the rat hypothalamic structures
(Simm et al., 2015); (iii) augment excitotoxicity produced by NMDA in mice (Iadecola et al.,
2001); and (iv) augment glutamate induced excitotoxicity in hippocampal slices via EP3R
activation (Ikeda-Matsuo, 2013).
The GPR109A expression in the RVLM TH-ir (presympathetic) neurons (Rezq and
Abdel-Rahman, 2015) is functionally important because its activation significantly increased
c-Fos expression, which reflects neuronal activity (Bullitt, 1990), in the same neuronal pool
(Fig. 4.5C). These findings suggest sympathoexcitatory action for GPR109A, which is
further supported by the spectral analysis findings in the same rats (Fig. 3). Importantly, the
ability of local EP3R blockade to abrogate the NA-evoked increases in c-Fos expression in
TH-ir neurons (Fig. 4.5D) and in sympathetic dominance (Fig. 4.3) implicates EP3R
signaling in RVLM GPR109A-mediated sympathoexcitation. It was important, however, to
determine the implicated molecular mechanisms in this neuronal response, particularly the
oxidative stress in the RVLM.
A number of studies including ours directly linked RVLM ERK1/2 phosphorylation to
central sympathoexcitation, at least partly, via activation of nNOS (Chan et al., 2010;
Ibrahim and Abdel-Rahman, 2012) because nNOS-derived NO inhibits RVLM GABAergic
neurotransmission and induces sympathoexcitation in conscious rats (Martins-Pinge et al.,
2007; Ibrahim and Abdel-Rahman, 2011). Further, nNOS derived NO can contribute to ROS
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generation by interacting with super oxide radicle to produce peroxynitrite (Beckman et al.,
1990) and to L-glutamate release (McNaught and Brown, 1998; Bal-Price et al., 2002). The
involvement of ERK1/2 pathway in PGE2-EP3R mediated signaling in other models
(Chuang et al., 2006; Nicola et al., 2008) presented a rationale to investigate this pathway in
the current study. We demonstrate substantial increases in local ERK1/2 and nNOS
phosphorylation following intra-RVLM NA (Fig. 4.6). These neuronal responses paralleled
the increase in RVLM TH neuronal activity (c-Fos; Fig. 5), and were all abrogated by local
EP3R blockade. Further, prior nNOS inhibition (NPLA) abolished the NA-evoked nNOS
phosphorylation and pressor response (Fig. 4.8) in rats and the increase in L-glutamate in
PC12 cells (Fig.4.9). These findings suggest a pivotal role for a PGE2/EP3R-dependent
increase in RVLM nNOS signaling in the GPR109A (NA)-mediated sympathoexcitation
taking into consideration the ability of EP3R blockade to abrogate nNOS phosphorylation
similar to NPLA (Fig. 4.6). These findings implicate PGE2/EP3 signaling in direct or indirect
nNOS phosphorylation.
It is important to comment on increased RVLM ROS formation as a viable mechanistic
link between the EP3R-dependent ERK1/2-nNOS activation and the sympathoexcitation
caused by RVLM GPR109A activation. This notion is supported by the findings that high
RVLM ROS level is associated with sympathoexcitation (increased c-Fos expression in TH-
ir neurons) in this study (Fig. 4.5), and in reported studies that showed that NOX-derived
superoxide anion activates ERK pathway with subsequent c-Fos induction and pressor
response (Chan et al., 2005; Chan et al., 2007). These findings are consistent with local
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PGE2 activation of NOX following central angiotensin II injection (Wang et al., 2013a). Our
conclusion is bolstered by the ability of both selective nNOS inhibition (NPLA) and EP3R
blockade (L-798106) to similarly abolish the increases in nNOS phosphorylation, c-Fos
intensity, ROS level and NOX activity, and to restore the reduced catalase activity in NA-
treated rats (Figs. 4.6, 7, 8 and 9) and to attenuate NA-mediated L-glutamate in cultured
PC12 cells (Fig. 4.9).
In conclusion, this study provides evidence that PGE2 activation of EP3R in the RVLM
contributes to the GPR109A (NA)-mediated sympathoexcitation and pressor response via
enhancing glutamatergic neurotransmission and oxidative stress. Further, we present novel
findings on the expression of EP3R, and PGE2-EP3R signaling, in the RVLM as well as the
molecular mechanisms for its sympathoexcitatory/pressor function acting alone or as a
mediator of GPR109A (NA)-evoked pressor response (Fig. 4.10). The present pharmacologic
and molecular findings may support a cardiovascular benefit for taking aspirin before NA in
hyperlipidemic patients, and suggest a potential use for central EP3R blockers as
antihypertensive medications.
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Figure 4.10. Suggested mechanisms for the role of PGE2/EP3R in GPR109A-mediated
pressor response.
Suggested mechanisms for the role of PGE2/EP3R in GPR109A-mediated pressor response
caused by nicotinic acid (NA) microinjection into the RVLM. The sequence of events is based
on the findings that: (i) Intra-RVLM GPR109A activation (NA) increased blood
pressure/sympathetic activity in conscious freely moving rats (Figs. 2 and 3), and increased
RVLM PGE2 (Fig. 1), c-Fos expression in TH-ir neurons (Fig. 5), p-ERK1/2 and p-nNOS levels
(Fig. 6), and oxidative stress (Fig. 7); (ii) NA increased intracellular calcium levels in PC12 cells
which exhibit a neuronal phenotype (Rezq and Abdel-Rahman, 2015) (iii) NA and PGE2
increased glutamate levels (Figs. 4) in PC12 cells; (iv) EP3R (L-798106) or nNOS blockade
(NPLA) attenuated the RVLM GPR109A-mediated biochemical and pressor responses (see text
for details).
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CHAPTER FIVE-GENERAL DISCUSSION AND SUMMARY
NA, a commonly used anti-hyperlipidemic drug, is known to produce a flushing reaction
via activating GPR109A receptor to increase intracellular calcium levels and the release of
different PGs including PGE2; the latter increases sympathetic activity and BP upon central
activation of its receptor (EP3R) in hypothalamic nuclei (Ando et al., 1995; Ariumi et al., 2002;
Murakami et al., 2002; Zhang et al., 2011). Additionally, both Ca2+(Kish and Ueda, 1991;
Berridge, 1998; Sudhof, 2004) and PGE2 (Bezzi et al., 1998; Wang et al., 2015) induce the
release of the sympathoexcitatory amino acid L- glutamate. The ability of NA to reach the brain
in appreciable concentrations following peripheral administration raised the possible contribution
of central GPR109A to cardiovascular regulation. The main goal of the current study was to
elucidate the role of GPR109A in central regulation of BP, and uncovering the contribution of
both l-glutamate and PGE2 to this role. As there are no previous reports on central expression of
GPR109A in the RVLM, the main cardiovascular regulating nucleus in the brain stem, we
demonstrated the expression of the receptor in this neuronal pool as well as in PC12 cells using
western blot (Fig. 3.1). Equally important, this was followed by elucidating the spatial
distribution of GPR109A relative to different cell types (glial and neuronal), giving special
attention to TH-ir neurons (Figs. 3.1 and 3.2), which regulate the sympathetic activity (Guyenet,
2006a; Kumagai et al., 2012). Our findings indicated a sharp robust increase in BP and a
decrease in HR following intra-RVLM injection of NA. The similarities between this response
and the response elicited by intra-RVLM L-glutamate (via NMDAR), inferred contribution of
the latter to NA-evoked pressor response. To investigate this interesting postulate, it was
important to utilize pharmacological interventions that target different glutamate receptors.
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Subsequent ex vivo and cell culture studies using PC12 cells elucidated the mechanisms
implicated in the central GPR109A-evoked pressor response in SD rats. In pursuit of this goal,
we characterized the centrally-elicited hemodynamic effects of GPR109A in conscious SD rats.
Intra-RVLM administration of GPR109A dose-dependently increased MAP and decreased HR,
suggesting a role of GPR109A in central BP regulation (Fig. 3.3). Interestingly, similar onset and
pattern were shared between the pressor responses elicited by intra-RVLM NA or L-glutamate
(Fig. 3.3A), and the latter replicated the findings in reported studies including ours (Bachelard et
al., 1990; Mao and Abdel-Rahman, 1994). These findings raised a potential link between NA and
L-glutamate, the main cardiovascular excitatory amino acid. This notion was supported by the
findings that the NA-evoked pressor response was abolished by prior NMDAR (AP5), but not
with non-NMDAR (CNQX), blockade, and was exacerbated with prior glutamate uptake
inhibition (PDC) (Fig. 3.4). While the rapid onset of the pressor response (Fig. 3.3A) precluded
investigation of NA effect on RVLM L-glutamate release, we adopted direct biochemical
measurements in PC12 cells to support L-glutamate involvement in the NA-evoked
cardiovascular responses. The ability of NA to increase Ca2+ levels in cultured PC12 cells, which
is consistent with other findings showing that NA (10 µM-3 mM) mediates a GPR109A
dependent increase in intracellular Ca2+ levels in macrophages and epidermal Langerhans cells
(Benyo et al., 2005; Benyo et al., 2006; Vanhorn et al., 2012; Gaidarov et al., 2013), is important
because Ca2+ triggers L-glutamate release (Kish and Ueda, 1991; Berridge, 1998; Sudhof, 2004)
and GPR109A-mdiated PGs release (Benyo et al., 2005). It is imperative, nonetheless, to note
that these cardiovascular responses were mediated via NA activation of RVLM GPR109A
because the inactive NA isomer, IsoNA (similar dose in vivo and concentration in vitro), failed
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to produce similar cardiovascular and biochemical effects (Fig. 3.4, A and B). Next, we targeted
ROS as the main molecular mechanism that underlies L-glutamate mediated sympathoexcitation
(Albrecht et al., 2010) to support our L-glutamate hypothesis. Ex vivo studies on RVLM tissues
revealed higher ROS level in NA-treated rats, which was attenuated by prior NMDAR blockade
(AP5), and exacerbated by glutamate uptake inhibition (PDC). These biochemical responses
paralleled the changes in NA-evoked pressor response in these treatment groups (Figs. 3.4 and
5). Moreover, in vitro studies in PC12 cells demonstrated that NA (1 mM) and L-glutamate, in a
concentration (100 nM) similar to that released by NA (1 mM), produced comparable increases
in oxidative stress, an effect that was abrogated with prior NMDAR blockade (Fig. 3.7). The
above-mentioned effects are mediated via GPR109A activation because the use of the inactive
isomer, IsoNA failed to produce hemodynamic or biochemical changes that are significantly
different from untreated controls (Figs. 3.5,6 and 7). Equally important, NA failed to increase
Ca2+ or glutamate levels in PC12 cells following siRNA-evoked GPR109A knockdown (Fig.
3.8).
In the second part of this research project, we aimed to investigate whether PGs, in
particular PGE2, which is reported among other PGs to elicit a sympathoexcitatory response
when injected centrally specifically via activating EP3R, is involved in NA-mediated pressor
response at least partially via enhancing L-glutamate release. We elucidated the ability of NA to
increase PGE2 release in both RVLM and PC12 cells. Although EP3R is expressed in other brain
areas (Kotani et al., 1995), there is no evidence on the expression or function of EP3R in the
RVLM. Further, the effect of local PGE2 in the RVLM on BP was not reported before. Here, we
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demonstrated, for the first time, EP3R expression in the RVLM and in PC12 cells. Next, we
demonstrated the effect of locally injecting PGE2 in the RVLM on BP and HR. Further, we
investigated the effect of the selective EP3R blockade, the subtype of PGE2 receptors we
hypothesized that it mediates the PGE2-evoked sympathoexcitatory activity, based on reported
findings in other brain areas (Ariumi et al., 2002; Zhang et al., 2011). As first step, the current
findings demonstrated the expression of EP3R in both the RVLM and PC12 cells (Fig. 4.1).
Intra-RVLM PGE2 increased BP that was abolished with prior EP3R blockade, which also
attenuated NA-mediated pressor response (Fig. 4.2) and adverse autonomic changes (Fig. 4.3).
These in vivo findings extend the sympathoexcitatory role of PGE2/EP3R, described in
hypothalamic nuclei (Ando et al., 1995; Ariumi et al., 2002; Murakami et al., 2002; Zhang et al.,
2011), to the RVLM. Subsequent molecular studies indicated that the increase in L-glutamate in
cultured PC12 cells was mediated, at least partially, by locally released PGE2 via EP3R because
selective EP3R blockade attenuated this effect (Fig. 4.4). This finding is consistent with reported
findings on the ability of: (i) PGE2 to increase both L-glutamate level and glutamatergic
neurotransmission in cultured neurons and mice (Bezzi et al., 1998; Iadecola et al., 2001; Simm
et al., 2015; Wang et al., 2015) (Iadecola et al., 2001), and (ii) EP3R antagonism to attenuate
glutamate induced excitotoxicity in hippocampal slices (Ikeda-Matsuo, 2013). Another evidence
for the role of EP3R in PGE2-mediated sympathoexcitation is the ability of its antagonist to
attenuate the intra-RVLM neuronal reactivity (c-Fos expression) elicited by intra-RVLM PGE2
(Fig. 4.5).
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The next step was to investigate molecular mechanisms involved in the pressor response
elicited by intra-RVLM NA as a downstream of PGE2 release. We reasoned that PGE2 ability to
increase NOX activity (Wang et al., 2013a), c-Fos expression in different brain areas involved in
cardiovascular and autonomic regulation (Lacroix et al., 1996; Zhang et al., 2011), and ERK1/2
pathway activation (Chuang et al., 2006) are sufficient molecular mechanisms for central PGE2-
evoked pressor response because these biochemical responses lead to sympathoexcitation and BP
increase (Chalmers et al., 1994; Minson et al., 1994; Ibrahim and Abdel-Rahman, 2012; Chen et
al., 2013). Therefore, we utilized a multilevel experimental approach to investigate these novel
and interrelated possibilities. In our model, NA increased c-Fos expression, ERK1/2 and nNOS
phosphorylation and oxidative stress (elevated ROS levels, increased NOX activity and
decreased catalase activity). The previously mentioned effects were all blocked by prior EP3R
blockade, suggesting that: (i) locally released PGE2 in the RVLM mediates these effects, which
ultimately leads to the pressor response elicited by NA; and (ii) EP3R among other PGE2
receptors is pivotal for PGE2-evoked sympathoexcitatory actions in the RVLM.
We tested the hypothesis that nNOS activation (increased NO generation), at least partly
via ERK1/2 activation, plays important role in the EP3R-dependent pressor response caused by
intra-RVLM NA for the following reasons. First, reported studies including ours showed that the
RVLM ERK1/2-nNOS pathway is implicated in sympathoexcitation (Martins-Pinge et al., 2007;
Chan et al., 2010; Ibrahim and Abdel-Rahman, 2011; Ibrahim and Abdel-Rahman, 2012).
Second, this signaling pathway is implicated in the PGE2-EP3R mediated effects in other model
systems (Chuang et al., 2006; Nicola et al., 2008), and in L-glutamate mediated neurotoxicity
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(Garthwaite et al., 1988; Dawson et al., 1993). Third, NA-mediated pressor response was
associated with higher p-nNOS level in our model system (Figs. 4.6) that was decreased with
prior EP3R blockade. Based on biochemical findings that supported our hypothesis, we extended
our in vivo studies (Fig. 4.8) to establish biological relevance for this signaling pathway by
investigating the effect of local selective nNOS blockade (NPLA) on biochemical events in the
RVLM and the pressor response caused by intra-RVLM NA. We showed that NPLA abrogated
NA-evoked increase in L-glutamate in PC12 cells and the following neurochemical responses in
the RVLM: c-Fos expression and oxidative stress (increased ROS and NOX activity and
decreased catalase activity). Equally important, nNOS inhibition in the RVLM abolished the
pressor responses caused by intra RVLM NA, which suggested a viable mechanistic link
between the EP3R-dependent ERK1/2 activation and the sympathoexcitation caused by RVLM
GPR109A activation. This notion is supported by the findings that high RVLM ROS level is
associated with sympathoexcitation (increased c-Fos expression in TH-ir neurons) in this study
(Fig. 4.5), and in reported studies that showed that NOX-derived superoxide anion activates ERK
pathway with subsequent c-Fos induction and pressor response (Chan et al., 2005; Chan et al.,
2007). Although, others implicated RVLM ERK1/2-nNOS activation in hypotensive responses
(El-Mas et al., 2009; Kastenmayer et al., 2012) (Kagiyama et al., 1997), which raises the
possibility that GPR109A-mediated increase in NO levels could ultimately oppose the pressor
effect of intra-RVLM NA. We found that selective nNOS blockade (NPLA) significantly
attenuated NA-elicited pressor response and oxidative stress (Fig. 4.8), which rules out this
possibility in our model system. Further, similar to EP3R blockade, NPLA abrogated NA-
mediated increase in L-glutamate (PC12 cells) and RVLM c-Fos expression (Fig. 4.9) lending
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more support to our hypothesis and agrees with reported ability of NO to increase L-glutamate
release (McNaught and Brown, 1998; Bal-Price et al., 2002) and c-Fos expression (Chan et al.,
2004). Collectively, this part of the study suggested that PGE2 is critical for the glutamate-
mediated pressor response elicited by NA directly by enhancing glutamate release (Fig. 4.4) or
indirectly by triggering signaling pathways that contribute to this sympathoexcitatory response,
in particular the ERK1/2-nNOS signaling pathway with its associated oxidative stress.
In summary, the present study presents the first evidence for GPR109A expression in the
RVLM, and its mediation of sympathoexcitation and elevation of BP via L-glutamate/NMDAR-
dependent mechanisms (Fig. 3.9). Additionally, this study provides evidence that PGE2
activation of EP3R in the RVLM contributes to the GPR109A (NA)-mediated
sympathoexcitation and pressor response via enhancing glutamatergic neurotransmission and
oxidative stress. Further, we present novel findings on the expression of EP3R in the RVLM as
well as the implicated molecular mechanisms of its sympathoexcitatory/pressor function (Fig.
4.9). Moreover, the present findings might have pathophysiological ramifications, particularly in
hypertension for three reasons. First, there is a clear link between an exacerbated RVLM
neuronal oxidative stress and the elevated BP in hypertension (Wu et al., 2014). Second,
compared to normotensive controls, activation of RVLM NMDAR causes greater elevation in
BP in spontaneously hypertensive rats (Lin et al., 1995). Third, the present findings may support
a cardiovascular benefit for taking aspirin before NA in hyperlipidemic patients, and suggest a
potential use for central EP3R blockers as antihypertensive medications. Collectively, the
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present findings, along with these reported studies, highlight central GPR109A as well as EP3R
as molecular targets for the development of novel antihypertensive medications.
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LIMITATIONS
1. The L-glutamate, a major player of NA pressor response, release was only assessed in
vitro in cultured PC12 cells. This alternative approach was adopted because the rapid
onset (1 min) of the L-glutamate-dependent pressor response elicited by NA precluded in
vivo measurement of L-glutamate even by microdialysis (Wang et al., 2005). The
microdialysis probe size is relatively big for small area like the RVLM and the 15-min
time intervals needed for dialysate collection, also precluded the use of that technique in
our studies.
2. PC12 cells are derived from a transplantable rat adrenal medulla pheochromocytoma
cells. Importantly, PC12 cells respond to nerve growth factor (NGF) by converting to
sympathetic-neuron-like phenotype (Greene and Rein, 1977; Greene, 1978). Further,
PC12 cells are tyrosine hydroxylase expressing cells.  Based on these characteristics,
these cells have been used in many reported studies including ours to conduct in vitro
studies that are not feasible in the RVLM in vivo (Separovic et al., 1997; Zhang and
Abdel-Rahman, 2005; Zhang and Abdel-Rahman, 2008) due to time or tissue limitations
such as calcium, glutamate and NO measurements. Nonetheless, PC12 cells have their
own limitations as there is no guarantee that the exact phenotype that those cells will
acquire upon differentiation will mimic that of RVLM neurons. Therefore, a primary
RVLM neuronal cell culture would be a better future approach. GPR109A is known to be
expressed in microglia (Penberthy, 2009), which might offer the use of microglial cell
line as another alternative model system for our in vitro studies.
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3. PGE2, which is known among other PGs to be sympathoexcitatory, can act through a
number of receptors including EP1, EP2, EP3, and EP4 receptors (Narumiya et al., 1999).
Although EP3R mediates the central cardiovascular excitatory effects and renal
sympathetic nerve activity of PGE2 in other studies (Ariumi et al., 2002; Zhang et al.,
2011) and that similar results were obtained in the current study, our conclusion will be
bolstered by investigating the role of other PGs known to be released by NA in the
periphery as well as other prostanoid receptors subtypes. Nonetheless, the present
findings are the first to implicate PGE2/EP3R signaling in the RVLM in
sympathoexcitation and as intermediary neurochemical mechanism for GPR109A (NA)-
evoked pressor response.
4. The effect of ERK1/2-nNOS signaling on NA-mediated pressor response was based on
the ability of NA to enhance both ERK1/2 and nNOS phosphorylation, compared to the
control group. While we presented pharmacological (NPLA) and biochemical (inhibition
of nNOS phosphorylation) that supported a causal role for nNOS phosphorylation in the
NA-mediated pressor response, it might be important to show that the latter was
secondary to ERK1/2 activation by pharmacologically inhibiting the latter in the RVLM.
Notably, our previous studies established such link in the RVLM of conscious rats
(Ibrahim and Abdel-Rahman, 2012).
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FUTURE DIRECTIONS
The present findings suggest a novel role for brainstem PGE2-EP3R signaling in the
central GPR109A-evoked pressor response. Importantly, the findings are the first to suggest a
sympathoexcitatory role for PGE2 in the RVLM, the major cardiovascular regulating nucleus in
the brain stem. Further, the study provides a novel insight into the suggested mechanisms that are
involved in PGE2 sympathoexcitatory actions, mainly through ERK1/2-nNOS phosphorylation.
In support of these findings, future studies are needed to elucidate the role of PGE2 relative to
other PGs (for example PGD2 and PGI2) and the role of EP3R relative to other prostanoid
receptors (EP1, EP2 or EP4). Our preliminary experiments in PC12 cells revealed that upon
using the concentration range applied throughout the study, both NA (1 mM) and PGE2 (10 µM)
induced mild decrease in cell viability following 24 hrs incubation and this effect was also
abolished with prior EP3R blockade (L-798106, 10µM) (Fig. 5.1). Future mechanistic studies are
warranted to elucidate the PGE2-mediated neurotoxic effect (via EP3R) using serial dilutions of
PGE2 in cultured PC12 cells as well as conducting ex vivo studies following longer time window
after intra-RVLM PGE2 (24-48 hrs after treatment). Such studies will advance our knowledge of
the role of PGs in the neural control of BP, in particular in conditions of systemic inflammation
or disease states that are associated with pressor responses and neurotoxicity/sympathoexcitation
such as cerebral stroke. Future clinical/epidemiological studies are needed to evaluate the benefit
for the concurrent use of small doses of aspirin to confer cardiovascular protection against an
overlooked central sympathoexcitation that potentially occurs in patients who receive NA for the
treatment of dyslipidemia. Finally, future studies are needed in models of experimental
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hypertension to test the hypothesis that EP3R signaling in the RVLM is hyperactive and to
examine the potential therapeutic value for central EP3R blockade in hypertension.
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Figure 5.1. NA induces apoptosis in PC12 cells via EP3R
(A) Effect of NA (100 µM, 1mM and 10mM), or IsoNA (10mM) on PC12 cell viability.
Measurements were done 24 hrs incubation time using MTS assay. Data representing folds of
vehicle treated cells and presented as mean ± S.E.M. (B) Effect of 24 hrs exposure of PC12 cells
to NA (1mM) or PGE2 (10 µM) on cell viability (folds increase of control) with or without 30
min prior incubation with the selective EP3R blocker, L-798106 (0.1 nmol). Data are expressed
as mean ± S.E.M. *P < 0.05 vs. control values; #P < 0.05 vs. NA; ^P < 0.05 vs. PGE2.
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